	Page 1
1	
2	U.S. FOOD & DRUG ADMINISTRATION
3	Assessment of FDA Hiring and Retention
4	
5	Thursday, November 30, 2017
6	9:00 a.m.
7	
8	
9	U.S. Food & Drug Administration
10	White Oak Campus, Bldg. 31, Great Room A
11	10903 New Hampshire Avenue
12	Silver Spring, MD 20993
13	301-796-0674
14	
15	
16	
17	
18	
19	
20	
21	
22	Reported by: Irene Gray

	Page 2		Page 4
1	A P P E A R A N C E S	1	P R O C E E D I N G S
2		2	INTRODUCTION
3	Rachel Sherman, Principal Deputy Commissioner	3	DR. SHERMAN: Good morning, I'll just wait
4	Steven Berman, Operations Research Analyst	4	until everyone gets seated.
5	Melanie Keller, Acting Associate Commissioner for	5	Good morning again. My name is Rachel
6	Scientific and Clinical Recruitment	6	Sherman. I'm a Principal Deputy Commissioner and it is
7	Tania Tse, Director, Office of Human Resources	7	my pleasure to welcome you to our, I think it is our
8	Angel Hebert, Deputy Chief of Operations	8	first public meeting ever on hiring and retention.
9		9	The purpose of today's meeting is to update
10		10	you on several of the programs we have ongoing to
11		11	modernize our hiring process and our retention process.
12		12	This meeting is a commitment under PDUFA VI and BsUF
13		13	II but this is not a check your box exercise.
14		14	The meeting, the idea of transparency
15		15	discussion and feedback is something that has worked
16		16	for us extremely well in the scientific area and now we
17		17	are bringing those, if you will, first principles into
18		18	an operations area.
19		19	There is nothing more important to us, to FDA,
20		20	than our workforce in being able to serve the public.
21		21	And we've grown very rapidly and like many
22		22	bureaucracies our processes have not kept up with our
	Page 3		Page 5
1	Page 3 CONTENTS	1	Page 5 growth.
1 2	-	1	growth.
2	CONTENTS	2	
2 3	C O N T E N T S Page	2 3	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the
2 3 4	C O N T E N T S Page INTRODUCTION	2 3 4	growth. And we are particularly appreciative to Dr.
2 3 1 4 1 5 1	CONTENTS Page INTRODUCTION Rachel Sherman 4	2 3 4 5	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources
2 3 4 5 6	CONTENTS Page INTRODUCTION Rachel Sherman 4 FDA HIRING ASSESSMENT: FINDINGS AND RECOMMENDATIONS	2 3 4 5 6	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as
2 3 4 5 6 7	CONTENTS Page INTRODUCTION Rachel Sherman 4 FDA HIRING ASSESSMENT: FINDING AND RECOMMENDATIONS Steven Berman 7	2 3 4 5 6 7	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as possible. And we also very much appreciate the support
2 3 4 5 6 7	CONTENTS Page INTRODUCTION Rachel Sherman 4 FDA HIRING ASSESSMENT: FINDINGS AND RECOMMENDATIONS Steven Berman 7 FDA PDUFA VI AND BsUFA II HIRING & RETENTION PROGRESS	2 3 4 5 6 7 8	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as possible. And we also very much appreciate the support of CBER and CDER and Dr. Woodcock not only for sitting
2 3 1 4 1 5 1 6 1 7 1 8 2	CONTENTS Page INTRODUCTION Rachel Sherman 4 FDA HIRING ASSESSMENT: FINDING SAND RECOMMENDATIONS Steven Berman 7 FDA PDUFA VI AND BSUFA II HIRING & RETENTION PROGRESS Tania Tse	2 3 4 5 6 7 8 9	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as possible. And we also very much appreciate the support of CBER and CDER and Dr. Woodcock not only for sitting on our steering committee wisdom but also for lending
2 3 1 4 1 5 1 6 1 7 1 8 2 9 1	CONTENTS Page INTRODUCTION Rachel Sherman 4 FDA HIRING ASSESSMENT: FINDINGS AND RECOMMENDATIONS Steven Berman 7 FDA PDUFA VI AND BsUFA II HIRING & RETENTION PROGRESS Tania Tse 18	2 3 4 5 6 7 8 9 10	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as possible. And we also very much appreciate the support of CBER and CDER and Dr. Woodcock not only for sitting on our steering committee wisdom but also for lending us one of her senior managers which I'll describe in a
2 3 4 5 5 6 7 1 8 7 1 8 7 1 8 7	CONTENTS Page INTRODUCTION Rachel Sherman 4 FDA HIRING ASSESSMENT: FINDINGS AND RECOMMENDATIONS Steven Berman 7 FDA PDUFA VI AND BsUFA II HIRING & RETENTION PROGRESS Tania Tse 18 Melanie Keller 26	2 3 4 5 6 7 8 9 10 11	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as possible. And we also very much appreciate the support of CBER and CDER and Dr. Woodcock not only for sitting on our steering committee wisdom but also for lending us one of her senior managers which I'll describe in a moment.
2 3 4 5 5 6 7 1 8 7 1 8 7 1 8 7 1 10 1 11	CONTENTS Page INTRODUCTION Rachel Sherman FDA HIRING ASSESSMENT: FINDINGS AND RECOMMENDATIONS Steven Berman 7 FDA PDUFA VI AND BsUFA II HIRING & RETENTION PROGRESS Tania Tse 18 Melanie Keller 26 REIMAGINE FDA HIRING PILOT	2 3 4 5 6 7 8 9 10 11 12	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as possible. And we also very much appreciate the support of CBER and CDER and Dr. Woodcock not only for sitting on our steering committee wisdom but also for lending us one of her senior managers which I'll describe in a moment. So today we are going to focus on three
2 3 4 5 5 6 7 1 8 7 1 8 7 1 8 7 1 10 1 11 12	CONTENTS Page INTRODUCTION Rachel Sherman 4 FDA HIRING ASSESSMENT: FINDINGS AND RECOMMENDATIONS Steven Berman 7 FDA PDUFA VI AND BsUFA II HIRING & RETENTION PROGRESS Tania Tse 18 Melanie Keller 26 REIMAGINE FDA HIRING PILOT Melanie Keller 29	2 3 4 5 6 7 8 9 10 11 12 13	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as possible. And we also very much appreciate the support of CBER and CDER and Dr. Woodcock not only for sitting on our steering committee wisdom but also for lending us one of her senior managers which I'll describe in a moment. So today we are going to focus on three primary things. We've conducted, again this was a
2 3 4 5 5 6 7 7 8 7 8 7 10 10 11 11 12 11 13	CONTENTS Page INTRODUCTION Rachel Sherman 4 FDA HIRING ASSESSMENT: FINDURGS AND RECOMMENDATIONS Steven Berman 7 FDA PDUFA VI AND BsUFA II HIRING & RETENTION PROGRESS Tania Tse Melanie Keller 26 REIMAGINE FDA HIRING PILOT Melanie Keller 29 PUBLIC COMMENT 37	2 3 4 5 6 7 8 9 10 11 12 13 14	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as possible. And we also very much appreciate the support of CBER and CDER and Dr. Woodcock not only for sitting on our steering committee wisdom but also for lending us one of her senior managers which I'll describe in a moment. So today we are going to focus on three primary things. We've conducted, again this was a commitment, a comprehensive evaluation of our hiring
2 3 4 5 5 6 7 7 8 7 8 7 10 10 11 11 12 11 13	CONTENTS Page INTRODUCTION Rachel Sherman 4 FDA HIRING ASSESSMENT: FINDINGS AND RECOMMENDATIONS Steven Berman 7 FDA PDUFA VI AND BSUFA II HIRING & RETENTION PROGRESS Tania Tse 18 Melanic Keller 26 REIMAGINE FDA HIRING PILOT Melanic Keller 29 PUBLIC COMMENT 37 CLOSING	2 3 4 5 6 7 8 9 10 11 12 13 14 15	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as possible. And we also very much appreciate the support of CBER and CDER and Dr. Woodcock not only for sitting on our steering committee wisdom but also for lending us one of her senior managers which I'll describe in a moment. So today we are going to focus on three primary things. We've conducted, again this was a commitment, a comprehensive evaluation of our hiring practices. So we now understand the current state. The
2 3 4 5 7 6 7 7 8 7 1 8 7 1 8 7 1 8 7 1 8 7 1 8 7 1 1 1 1	CONTENTS Page INTRODUCTION Rachel Sherman 4 FDA HIRING ASSESSMENT: FINDINGS AND RECOMMENDATIONS Steven Berman 7 FDA PDUFA VI AND BSUFA II HIRING & RETENTION PROGRESS Tania Tse 18 Melanic Keller 26 REIMAGINE FDA HIRING PILOT Melanic Keller 29 PUBLIC COMMENT 37 CLOSING	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as possible. And we also very much appreciate the support of CBER and CDER and Dr. Woodcock not only for sitting on our steering committee wisdom but also for lending us one of her senior managers which I'll describe in a moment. So today we are going to focus on three primary things. We've conducted, again this was a commitment, a comprehensive evaluation of our hiring practices. So we now understand the current state. The report was published on the Web about two weeks ago.
2 3 4 5 1 6 7 1 8 7 1 8 7 1 8 7 1 8 7 1 8 7 1 1 1 1	CONTENTS Page INTRODUCTION Rachel Sherman 4 FDA HIRING ASSESSMENT: FINDINGS AND RECOMMENDATIONS Steven Berman 7 FDA PDUFA VI AND BSUFA II HIRING & RETENTION PROGRESS Tania Tse 18 Melanic Keller 26 REIMAGINE FDA HIRING PILOT Melanic Keller 29 PUBLIC COMMENT 37 CLOSING	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as possible. And we also very much appreciate the support of CBER and CDER and Dr. Woodcock not only for sitting on our steering committee wisdom but also for lending us one of her senior managers which I'll describe in a moment. So today we are going to focus on three primary things. We've conducted, again this was a commitment, a comprehensive evaluation of our hiring practices. So we now understand the current state. The report was published on the Web about two weeks ago. And you will get a detailed summary of that today.
2 3 4 5 5 6 7 1 8 7 1 8 7 1 8 7 1 8 7 1 8 7 1 1 1 1	CONTENTS Page INTRODUCTION Rachel Sherman 4 FDA HIRING ASSESSMENT: FINDINGS AND RECOMMENDATIONS Steven Berman 7 FDA PDUFA VI AND BSUFA II HIRING & RETENTION PROGRESS Tania Tse 18 Melanic Keller 26 REIMAGINE FDA HIRING PILOT Melanic Keller 29 PUBLIC COMMENT 37 CLOSING	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as possible. And we also very much appreciate the support of CBER and CDER and Dr. Woodcock not only for sitting on our steering committee wisdom but also for lending us one of her senior managers which I'll describe in a moment. So today we are going to focus on three primary things. We've conducted, again this was a commitment, a comprehensive evaluation of our hiring practices. So we now understand the current state. The report was published on the Web about two weeks ago. And you will get a detailed summary of that today. Then in addition we will be discussing the
2 3 4 5 7 8 7 8 7 8 7 8 7 8 7 8 7 10 11 12 11 12 11 12 11 11 11 11 11 11 11	CONTENTS Page INTRODUCTION Rachel Sherman 4 FDA HIRING ASSESSMENT: FINDINGS AND RECOMMENDATIONS Steven Berman 7 FDA PDUFA VI AND BSUFA II HIRING & RETENTION PROGRESS Tania Tse 18 Melanic Keller 26 REIMAGINE FDA HIRING PILOT Melanic Keller 29 PUBLIC COMMENT 37 CLOSING	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as possible. And we also very much appreciate the support of CBER and CDER and Dr. Woodcock not only for sitting on our steering committee wisdom but also for lending us one of her senior managers which I'll describe in a moment. So today we are going to focus on three primary things. We've conducted, again this was a commitment, a comprehensive evaluation of our hiring practices. So we now understand the current state. The report was published on the Web about two weeks ago. And you will get a detailed summary of that today. Then in addition we will be discussing the progress that we've made to date on BsUFA and PDUFA
2 3 4 5 5 6 7 7 8 7 1 8 7 1 8 7 1 8 7 1 8 7 1 1 1 1	CONTENTS Page INTRODUCTION Rachel Sherman 4 FDA HIRING ASSESSMENT: FINDINGS AND RECOMMENDATIONS Steven Berman 7 FDA PDUFA VI AND BSUFA II HIRING & RETENTION PROGRESS Tania Tse 18 Melanic Keller 26 REIMAGINE FDA HIRING PILOT Melanic Keller 29 PUBLIC COMMENT 37 CLOSING	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as possible. And we also very much appreciate the support of CBER and CDER and Dr. Woodcock not only for sitting on our steering committee wisdom but also for lending us one of her senior managers which I'll describe in a moment. So today we are going to focus on three primary things. We've conducted, again this was a commitment, a comprehensive evaluation of our hiring practices. So we now understand the current state. The report was published on the Web about two weeks ago. And you will get a detailed summary of that today. Then in addition we will be discussing the progress that we've made to date on BsUFA and PDUFA commitments and in hiring in general. The last two
2 3 4 5 7 8 7 8 7 8 7 8 7 8 7 10 11 12 11 12 11 12 11 11 11 11 11 11 11	CONTENTS Page INTRODUCTION Rachel Sherman 4 FDA HIRING ASSESSMENT: FINDINGS AND RECOMMENDATIONS Steven Berman 7 FDA PDUFA VI AND BSUFA II HIRING & RETENTION PROGRESS Tania Tse 18 Melanic Keller 26 REIMAGINE FDA HIRING PILOT Melanic Keller 29 PUBLIC COMMENT 37 CLOSING	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	growth. And we are particularly appreciative to Dr. Theresa Mullin and others who are involved in the PDUFA/BsUFA negotiations to make sure not only that our attention was called to this but that we have resources that we need to move this forward as quickly as possible. And we also very much appreciate the support of CBER and CDER and Dr. Woodcock not only for sitting on our steering committee wisdom but also for lending us one of her senior managers which I'll describe in a moment. So today we are going to focus on three primary things. We've conducted, again this was a commitment, a comprehensive evaluation of our hiring practices. So we now understand the current state. The report was published on the Web about two weeks ago. And you will get a detailed summary of that today. Then in addition we will be discussing the progress that we've made to date on BsUFA and PDUFA

	Page 6		Page 8
	terms of the pace of hiring despite CRs, despite		from Health and Human Services, the department which
	freezes and pending freezes. But it is not enough. We		FDA is a part of. Since then FDA has struggled
3	want to do more. We want to do better. We don't just	3	implementing successful hiring program. The office of
4	want to hire by brut force. We want a modern system	4	Human Resources is not alone in its struggle. The
5	that will meet our needs not only now but into the	5	entire hiring system from hiring managers in the
6	future.	6	medical product centers to the Office of Human
7	And the final piece we will be discussing is	7	Resources to the Offices of Management have been a part
8	the hiring pilot that we will be very shortly	8	of the struggle.
9	launching. And that is where we are testing our new	9	As Dr. Sherman mentioned the Agency has a long
10	processes and methods and where we will refine them so	10	history of successful implementation of substantial
11	that they can serve the larger Agency.	11	improvements associated with user fee commitments. To
12	We also hope to get broad comment. And again	12	date most of those improvements have been focused on
13	in the scientific realm we often learn a lot from	13	technical regulatory activities. During this latest
14	dockets. There are people out there who know more than	14	round of user fee negotiations special attention was
15	we do about hiring amazingly. And so we would really	15	paid to other aspects of the functioning of the Food
16	appreciate any comments or thoughts that you have. We	16	and Drug Administration that could use improvements.
17	take these very seriously, we read them, study them. So	17	One that was singled out was the hiring process.
18	please take advantage of this.	18	So as part of the latest FDA Reauthorization
19	And again our goal is to continue to have a	19	Act, FDARA, passed recently in 2017 the Agency
20	world class workforce but make sure that we can keep up	20	committed to taking a hard look at improving its hiring
21	with the needs. This is a great place to work.	21	process so that the staff capacity can improve and so
22	Everyone is touched by hiring and retention. We either	22	that we can meet the technical regulatory goals of the
	Page 7		Page 9
1	Page 7 get hired or hiring or we work with someone who was	1	Page 9 Agency.
		1 2	
	get hired or hiring or we work with someone who was	2	Agency.
2 3	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs.	2 3	Agency. One commitment specified in the PDUFA VI and
2 3 4	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our	2 3 4	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party
2 3 4 5	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an	2 3 4 5	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the
2 3 4 5 6	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and	2 3 4 5	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their
2 3 4 5 6 7	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and understands how systems and businesses work. He joined	2 3 4 5 6 7	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their findings to you today.
2 3 4 5 6 7 8	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and understands how systems and businesses work. He joined the FDA about four years ago, first in CDER and now in	2 3 4 5 6 7 8	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their findings to you today. This assessment was focused on hiring with
2 3 4 5 6 7 8 9	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and understands how systems and businesses work. He joined the FDA about four years ago, first in CDER and now in the Office of the Commissioner. And he is going to	2 3 4 5 6 7 8 9	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their findings to you today. This assessment was focused on hiring with some attention paid to retention as well but I'm going
2 3 4 5 6 7 8 9	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and understands how systems and businesses work. He joined the FDA about four years ago, first in CDER and now in the Office of the Commissioner. And he is going to present the results of our report.	2 3 4 5 6 7 8 9 10	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their findings to you today. This assessment was focused on hiring with some attention paid to retention as well but I'm going to focus mostly on the hiring aspects of the report at
2 3 4 5 6 7 8 9 10	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and understands how systems and businesses work. He joined the FDA about four years ago, first in CDER and now in the Office of the Commissioner. And he is going to present the results of our report. FDA HIRING ASSESSMENT: Findings and Recommendations.	2 3 4 5 6 7 8 9 10 11	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their findings to you today. This assessment was focused on hiring with some attention paid to retention as well but I'm going to focus mostly on the hiring aspects of the report at this time. We did not examine things that were outside
2 3 4 5 6 7 8 9 10 11 12	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and understands how systems and businesses work. He joined the FDA about four years ago, first in CDER and now in the Office of the Commissioner. And he is going to present the results of our report. FDA HIRING ASSESSMENT: Findings and Recommendations. MR. BERMAN: Thank you and good morning.	2 3 4 5 6 7 8 9 10 11	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their findings to you today. This assessment was focused on hiring with some attention paid to retention as well but I'm going to focus mostly on the hiring aspects of the report at this time. We did not examine things that were outside of the control of FDA; like Health and Human Services
2 3 4 5 6 7 8 9 10 11 12 13	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and understands how systems and businesses work. He joined the FDA about four years ago, first in CDER and now in the Office of the Commissioner. And he is going to present the results of our report. FDA HIRING ASSESSMENT: Findings and Recommendations. MR. BERMAN: Thank you and good morning. I'm here as Dr. Sherman mentioned to present	2 3 4 5 6 7 8 9 10 11 12 13	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their findings to you today. This assessment was focused on hiring with some attention paid to retention as well but I'm going to focus mostly on the hiring aspects of the report at this time. We did not examine things that were outside of the control of FDA; like Health and Human Services or Office of Personnel Management Policies.
2 3 4 5 6 7 8 9 10 11 12 13 14	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and understands how systems and businesses work. He joined the FDA about four years ago, first in CDER and now in the Office of the Commissioner. And he is going to present the results of our report. FDA HIRING ASSESSMENT: Findings and Recommendations. MR. BERMAN: Thank you and good morning. I'm here as Dr. Sherman mentioned to present an overview of the diagnostic report that was published	2 3 4 5 6 7 8 9 10 11 12 13 14	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their findings to you today. This assessment was focused on hiring with some attention paid to retention as well but I'm going to focus mostly on the hiring aspects of the report at this time. We did not examine things that were outside of the control of FDA; like Health and Human Services or Office of Personnel Management Policies. At a high level the issues seen in the hiring
2 3 4 5 6 7 8 9 10 11 12 13 14 15	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and understands how systems and businesses work. He joined the FDA about four years ago, first in CDER and now in the Office of the Commissioner. And he is going to present the results of our report. FDA HIRING ASSESSMENT: Findings and Recommendations. MR. BERMAN: Thank you and good morning. I'm here as Dr. Sherman mentioned to present an overview of the diagnostic report that was published to the Web about two weeks ago. I'm going to speak	2 3 4 5 6 7 8 9 10 11 12 13 14 15	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their findings to you today. This assessment was focused on hiring with some attention paid to retention as well but I'm going to focus mostly on the hiring aspects of the report at this time. We did not examine things that were outside of the control of FDA; like Health and Human Services or Office of Personnel Management Policies. At a high level the issues seen in the hiring process are relatively well known. There are issues
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and understands how systems and businesses work. He joined the FDA about four years ago, first in CDER and now in the Office of the Commissioner. And he is going to present the results of our report. FDA HIRING ASSESSMENT: Findings and Recommendations. MR. BERMAN: Thank you and good morning. I'm here as Dr. Sherman mentioned to present an overview of the diagnostic report that was published to the Web about two weeks ago. I'm going to speak briefly about some context behind the report and then	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their findings to you today. This assessment was focused on hiring with some attention paid to retention as well but I'm going to focus mostly on the hiring aspects of the report at this time. We did not examine things that were outside of the control of FDA; like Health and Human Services or Office of Personnel Management Policies. At a high level the issues seen in the hiring process are relatively well known. There are issues with timeliness, accuracy, employee satisfaction,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and understands how systems and businesses work. He joined the FDA about four years ago, first in CDER and now in the Office of the Commissioner. And he is going to present the results of our report. FDA HIRING ASSESSMENT: Findings and Recommendations. MR. BERMAN: Thank you and good morning. I'm here as Dr. Sherman mentioned to present an overview of the diagnostic report that was published to the Web about two weeks ago. I'm going to speak briefly about some context behind the report and then go into some detail on an overview of the findings and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their findings to you today. This assessment was focused on hiring with some attention paid to retention as well but I'm going to focus mostly on the hiring aspects of the report at this time. We did not examine things that were outside of the control of FDA; like Health and Human Services or Office of Personnel Management Policies. At a high level the issues seen in the hiring process are relatively well known. There are issues with timeliness, accuracy, employee satisfaction, quality, and customer service. The amount of time that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and understands how systems and businesses work. He joined the FDA about four years ago, first in CDER and now in the Office of the Commissioner. And he is going to present the results of our report. FDA HIRING ASSESSMENT: Findings and Recommendations. MR. BERMAN: Thank you and good morning. I'm here as Dr. Sherman mentioned to present an overview of the diagnostic report that was published to the Web about two weeks ago. I'm going to speak briefly about some context behind the report and then go into some detail on an overview of the findings and the implication of those findings for hiring at the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their findings to you today. This assessment was focused on hiring with some attention paid to retention as well but I'm going to focus mostly on the hiring aspects of the report at this time. We did not examine things that were outside of the control of FDA; like Health and Human Services or Office of Personnel Management Policies. At a high level the issues seen in the hiring process are relatively well known. There are issues with timeliness, accuracy, employee satisfaction, quality, and customer service. The amount of time that it takes to hire for our mission critical occupations is long. Candidates have been frustrated with the high
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and understands how systems and businesses work. He joined the FDA about four years ago, first in CDER and now in the Office of the Commissioner. And he is going to present the results of our report. FDA HIRING ASSESSMENT: Findings and Recommendations. MR. BERMAN: Thank you and good morning. I'm here as Dr. Sherman mentioned to present an overview of the diagnostic report that was published to the Web about two weeks ago. I'm going to speak briefly about some context behind the report and then go into some detail on an overview of the findings and the implication of those findings for hiring at the FDA. So before we delve into an overview of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their findings to you today. This assessment was focused on hiring with some attention paid to retention as well but I'm going to focus mostly on the hiring aspects of the report at this time. We did not examine things that were outside of the control of FDA; like Health and Human Services or Office of Personnel Management Policies. At a high level the issues seen in the hiring process are relatively well known. There are issues with timeliness, accuracy, employee satisfaction, quality, and customer service. The amount of time that it takes to hire for our mission critical occupations is long. Candidates have been frustrated with the high number of errors and the length of the process as well
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and understands how systems and businesses work. He joined the FDA about four years ago, first in CDER and now in the Office of the Commissioner. And he is going to present the results of our report. FDA HIRING ASSESSMENT: Findings and Recommendations. MR. BERMAN: Thank you and good morning. I'm here as Dr. Sherman mentioned to present an overview of the diagnostic report that was published to the Web about two weeks ago. I'm going to speak briefly about some context behind the report and then go into some detail on an overview of the findings and the implication of those findings for hiring at the FDA. So before we delve into an overview of the report itself it might be useful to review some context	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their findings to you today. This assessment was focused on hiring with some attention paid to retention as well but I'm going to focus mostly on the hiring aspects of the report at this time. We did not examine things that were outside of the control of FDA; like Health and Human Services or Office of Personnel Management Policies. At a high level the issues seen in the hiring process are relatively well known. There are issues with timeliness, accuracy, employee satisfaction, quality, and customer service. The amount of time that it takes to hire for our mission critical occupations is long. Candidates have been frustrated with the high number of errors and the length of the process as well as the lack of communication throughout the hiring
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	get hired or hiring or we work with someone who was hired. And we want to be able to meet those needs. So I'd like to introduce our speaker. Our first speaker for today is Steve Berman. Steve is an Operations Research Analyst which means he studies and understands how systems and businesses work. He joined the FDA about four years ago, first in CDER and now in the Office of the Commissioner. And he is going to present the results of our report. FDA HIRING ASSESSMENT: Findings and Recommendations. MR. BERMAN: Thank you and good morning. I'm here as Dr. Sherman mentioned to present an overview of the diagnostic report that was published to the Web about two weeks ago. I'm going to speak briefly about some context behind the report and then go into some detail on an overview of the findings and the implication of those findings for hiring at the FDA. So before we delve into an overview of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Agency. One commitment specified in the PDUFA VI and BsUFA II commitment letters was to engage a third-party contractor to conduct a baseline assessment of the hiring system at FDA. I'm here to present their findings to you today. This assessment was focused on hiring with some attention paid to retention as well but I'm going to focus mostly on the hiring aspects of the report at this time. We did not examine things that were outside of the control of FDA; like Health and Human Services or Office of Personnel Management Policies. At a high level the issues seen in the hiring process are relatively well known. There are issues with timeliness, accuracy, employee satisfaction, quality, and customer service. The amount of time that it takes to hire for our mission critical occupations is long. Candidates have been frustrated with the high number of errors and the length of the process as well

1	Page 10		Page 12
	vacancies, have been dissatisfied with the amount of		Agency-wide with regard to the hiring process itself.
	transparency in the process and the quality of the		Hiring managers need better support.
	candidates who make it through. Incremental	3	Once all of the data was collected by the
	improvements to the hiring system have been tried		contractor in support of the commitment a root cause
	before.		framework was used to map that data into a larger
6	What I'm here to discuss today is something		context. We are going to review these findings in some
	new. We're approaching the entire hiring system		details now.
	systematically. The contractor was engaged to conduct	8	Here are the main findings at a high level.
	a baseline assessment to assist us with		The report online has significantly more detail about
	transformational change and modernization.		these.
11	This external contractor conducted extensive	11	First, it was determined that the process
12	I J C		documentation is incomplete which led to substantial
	the summer of 2016. Following data collection was the		variation in the execution of the process.
	analysis. All of this work was to inform a future	14	Secondly, the process suffers from substantial
	state that is highly responsive to the needs of the		complexity leading to poor timeliness and poor customer
	Agency is informed by data and by best practices.		satisfaction.
17	Let's begin by talking about some of the data	17	Third, there are unclear roles and
	collected and then we'll talk about the implications of		responsibilities in the process leading to confusion
	these data.		and poor accountability.
20	Here are some basic high-level facts and	20	Fourth, the IT systems are not user friendly
	figures about the current state. There is a lengthy		and are not integrated leading to low efficiency and
22	time to hire. It can take up to 550 days to hire for	22	poor transparency.
	Page 11		Page 13
	some mission critical occupations. There is a high	1	And finally, there is a finding of a lack of
2	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product	2	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor
2 3	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when	2 3	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication.
2 3 4	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is	2 3 4	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of
2 3 4 5	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low	2 3 4 5	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides.
2 3 4 5 6	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only	2 3 4 5 6	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that
2 3 4 5 6 7	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only 12% of hiring managers reporting being satisfied or	2 3 4 5 6 7	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that the hiring process itself is neither well designed nor
2 3 4 5 6 7 8	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only 12% of hiring managers reporting being satisfied or very satisfied with the hires.	2 3 4 5 6 7 8	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that the hiring process itself is neither well designed nor even fully defined. In sum it is not simple, not
2 3 4 5 6 7 8 9	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only 12% of hiring managers reporting being satisfied or very satisfied with the hires. On top of the quantitative and semi	2 3 4 5 6 7 8 9	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that the hiring process itself is neither well designed nor even fully defined. In sum it is not simple, not standardized, and not efficient in it current state.
2 3 4 5 6 7 8 9 10	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only 12% of hiring managers reporting being satisfied or very satisfied with the hires. On top of the quantitative and semi quantitative data that the contractor collected they	2 3 4 5 6 7 8 9 10	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that the hiring process itself is neither well designed nor even fully defined. In sum it is not simple, not standardized, and not efficient in it current state. The process is complicated. There are many steps
2 3 4 5 6 7 8 9 10 11	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only 12% of hiring managers reporting being satisfied or very satisfied with the hires. On top of the quantitative and semi quantitative data that the contractor collected they also spent a lot of time listening to what people were	2 3 4 5 6 7 8 9 10 11	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that the hiring process itself is neither well designed nor even fully defined. In sum it is not simple, not standardized, and not efficient in it current state. The process is complicated. There are many steps within each sub-process. There are many people
2 3 4 5 6 7 8 9 10 11 12	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only 12% of hiring managers reporting being satisfied or very satisfied with the hires. On top of the quantitative and semi quantitative data that the contractor collected they also spent a lot of time listening to what people were saying. There were numerous pain points identified	2 3 4 5 6 7 8 9 10 11 12	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that the hiring process itself is neither well designed nor even fully defined. In sum it is not simple, not standardized, and not efficient in it current state. The process is complicated. There are many steps within each sub-process. There are many people involved in each step. There are many handoffs between
2 3 4 5 6 7 8 9 10 11 12 13	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only 12% of hiring managers reporting being satisfied or very satisfied with the hires. On top of the quantitative and semi quantitative data that the contractor collected they also spent a lot of time listening to what people were saying. There were numerous pain points identified from various stakeholders.	2 3 4 5 6 7 8 9 10 11 12 13	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that the hiring process itself is neither well designed nor even fully defined. In sum it is not simple, not standardized, and not efficient in it current state. The process is complicated. There are many steps within each sub-process. There are many people involved in each step. There are many handoffs between steps causing delays and confusion. There are numerous
2 3 4 5 6 7 8 9 10 11 12 13 14	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only 12% of hiring managers reporting being satisfied or very satisfied with the hires. On top of the quantitative and semi quantitative data that the contractor collected they also spent a lot of time listening to what people were saying. There were numerous pain points identified from various stakeholders. Candidates were frustrated by the lack of	2 3 4 5 6 7 8 9 10 11 12 13 14	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that the hiring process itself is neither well designed nor even fully defined. In sum it is not simple, not standardized, and not efficient in it current state. The process is complicated. There are many steps within each sub-process. There are many people involved in each step. There are many handoffs between steps causing delays and confusion. There are numerous approvals throughout the process which create
2 3 4 5 6 7 8 9 10 11 12 13 14 15	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only 12% of hiring managers reporting being satisfied or very satisfied with the hires. On top of the quantitative and semi quantitative data that the contractor collected they also spent a lot of time listening to what people were saying. There were numerous pain points identified from various stakeholders. Candidates were frustrated by the lack of timeliness and transparency in the hiring process.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that the hiring process itself is neither well designed nor even fully defined. In sum it is not simple, not standardized, and not efficient in it current state. The process is complicated. There are many steps within each sub-process. There are many people involved in each step. There are many handoffs between steps causing delays and confusion. There are numerous approvals throughout the process which create bottlenecks but don't necessarily insure quality.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only 12% of hiring managers reporting being satisfied or very satisfied with the hires. On top of the quantitative and semi quantitative data that the contractor collected they also spent a lot of time listening to what people were saying. There were numerous pain points identified from various stakeholders. Candidates were frustrated by the lack of timeliness and transparency in the hiring process. Hiring managers were not satisfied with both their	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that the hiring process itself is neither well designed nor even fully defined. In sum it is not simple, not standardized, and not efficient in it current state. The process is complicated. There are many steps within each sub-process. There are many people involved in each step. There are many handoffs between steps causing delays and confusion. There are numerous approvals throughout the process which create bottlenecks but don't necessarily insure quality. It was determined that there is significant
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only 12% of hiring managers reporting being satisfied or very satisfied with the hires. On top of the quantitative and semi quantitative data that the contractor collected they also spent a lot of time listening to what people were saying. There were numerous pain points identified from various stakeholders. Candidates were frustrated by the lack of timeliness and transparency in the hiring process. Hiring managers were not satisfied with both their experience with the process and the outcomes of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that the hiring process itself is neither well designed nor even fully defined. In sum it is not simple, not standardized, and not efficient in it current state. The process is complicated. There are many steps within each sub-process. There are many people involved in each step. There are many handoffs between steps causing delays and confusion. There are numerous approvals throughout the process which create bottlenecks but don't necessarily insure quality. It was determined that there is significant confusion among hiring manager regarding the degree to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only 12% of hiring managers reporting being satisfied or very satisfied with the hires. On top of the quantitative and semi quantitative data that the contractor collected they also spent a lot of time listening to what people were saying. There were numerous pain points identified from various stakeholders. Candidates were frustrated by the lack of timeliness and transparency in the hiring process. Hiring managers were not satisfied with both their experience with the process and the outcomes of the process. The Human Resources specialists who actually	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that the hiring process itself is neither well designed nor even fully defined. In sum it is not simple, not standardized, and not efficient in it current state. The process is complicated. There are many steps within each sub-process. There are many people involved in each step. There are many handoffs between steps causing delays and confusion. There are numerous approvals throughout the process which create bottlenecks but don't necessarily insure quality. It was determined that there is significant confusion among hiring manager regarding the degree to which they themselves are responsible for preparing a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only 12% of hiring managers reporting being satisfied or very satisfied with the hires. On top of the quantitative and semi quantitative data that the contractor collected they also spent a lot of time listening to what people were saying. There were numerous pain points identified from various stakeholders. Candidates were frustrated by the lack of timeliness and transparency in the hiring process. Hiring managers were not satisfied with both their experience with the process and the outcomes of the process. The Human Resources specialists who actually conduct most of the hiring process itself were	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that the hiring process itself is neither well designed nor even fully defined. In sum it is not simple, not standardized, and not efficient in it current state. The process is complicated. There are many steps within each sub-process. There are many people involved in each step. There are many handoffs between steps causing delays and confusion. There are numerous approvals throughout the process which create bottlenecks but don't necessarily insure quality. It was determined that there is significant confusion among hiring manager regarding the degree to which they themselves are responsible for preparing a package and getting a candidate through the hiring
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only 12% of hiring managers reporting being satisfied or very satisfied with the hires. On top of the quantitative and semi quantitative data that the contractor collected they also spent a lot of time listening to what people were saying. There were numerous pain points identified from various stakeholders. Candidates were frustrated by the lack of timeliness and transparency in the hiring process. Hiring managers were not satisfied with both their experience with the process and the outcomes of the process. The Human Resources specialists who actually conduct most of the hiring process itself were	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that the hiring process itself is neither well designed nor even fully defined. In sum it is not simple, not standardized, and not efficient in it current state. The process is complicated. There are many steps within each sub-process. There are many people involved in each step. There are many handoffs between steps causing delays and confusion. There are numerous approvals throughout the process which create bottlenecks but don't necessarily insure quality. It was determined that there is significant confusion among hiring manager regarding the degree to which they themselves are responsible for preparing a package and getting a candidate through the hiring process. In a survey of approximately 140 hiring
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	some mission critical occupations. There is a high vacancy rate as well. Some of the medical product centers are seeing vacancy rates around 15% which when compared with benchmarks at other agencies is significantly higher. Finally there is low satisfaction with the quality of the outcomes with only 12% of hiring managers reporting being satisfied or very satisfied with the hires. On top of the quantitative and semi quantitative data that the contractor collected they also spent a lot of time listening to what people were saying. There were numerous pain points identified from various stakeholders. Candidates were frustrated by the lack of timeliness and transparency in the hiring process. Hiring managers were not satisfied with both their experience with the process and the outcomes of the process. The Human Resources specialists who actually conduct most of the hiring process itself were	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	And finally, there is a finding of a lack of collaborative and open dialogue leading to poor communication. Let's explore each of these in a little bit of detail over the next few slides. Results of a deep dive diagnosis showed that the hiring process itself is neither well designed nor even fully defined. In sum it is not simple, not standardized, and not efficient in it current state. The process is complicated. There are many steps within each sub-process. There are many people involved in each step. There are many handoffs between steps causing delays and confusion. There are numerous approvals throughout the process which create bottlenecks but don't necessarily insure quality. It was determined that there is significant confusion among hiring manager regarding the degree to which they themselves are responsible for preparing a package and getting a candidate through the hiring

	Page 14		Page 16
1	what was appropriate or expected. There is low	1	critical occupations. Candidates are frustrated by the
	accountability and low clarity in the process.		process. Hiring managers are frustrated by the
3	In additions to findings regarding process and		process. There are issues with accuracy, things from
4			spelling of people's names to the content of the
5	current IT systems that support the hiring process.		packages themselves. And customer service and employee
	There are more than six IT systems used that are not		satisfaction were also noted as needing improvement.
	integrated, not automated and not user-friendly. This	7	Following these root cause outcomes the
	has resulted in poor utilization rates of the systems.	8	contractor suggested that without a fundamental
9	And the proliferation of home grown center-based		redesign of the process, one that addresses the system,
	solutions.		the people, the process, and the culture FDA's ability
11	The lack of good data about the hiring process	11	to hire the right people at the right time in the right
12	has additional downstream effects. One major	12	way will continue to be impaired.
13	consequence of the state of the IT system is that there	13	To recap. Fulfilling a PDUFA VI and BsUFA II
14	is poor tracking of core metrics about how hiring	14	commitment a contractor was engaged to assess the
15	functions at the FDA. There are a few metrics collected	15	hiring process at FDA. Over 600 new hires were
16	that measure process timeliness. But these data have	16	surveyed. Nearly 200 hiring managers were surveyed.
17	questionable accuracy due to the manual nature of many	17	There were significant findings regarding process,
18	of the IT systems.	18	people, and systems.
19	There were no metrics identified to assess	19	The contractor recommended following a review
20	process accuracy, outcome quality, customer	20	of the data and the analysis to design and launch a
21	satisfaction, and employee satisfaction. Without these	21	controlled pilot one which has a clean sheet design,
22	core metrics accountability to the process is difficult	22	reconfigured stakeholder roles, one that explores new
	Page 15		Page 17
			Tage 17
1	to achieve. Further without these core metrics	1	sources of talent, and one that leverages technologies
			-
2	to achieve. Further without these core metrics	2	sources of talent, and one that leverages technologies
2	to achieve. Further without these core metrics performance improvement efforts are rendered	2 3	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was
2 3 4	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult.	2 3 4	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with
2 3 4 5	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the	2 3 4	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the
2 3 4 5 6	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the mindsets and behaviors observed at the Agency do not	2 3 4 5 6	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the design and to role out improvements FDA-wide.
2 3 4 5 6 7	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the mindsets and behaviors observed at the Agency do not support an effective and efficient hiring process. It	2 3 4 5 6 7	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the design and to role out improvements FDA-wide. It was recommended that the pilot be designed
2 3 4 5 6 7 8	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the mindsets and behaviors observed at the Agency do not support an effective and efficient hiring process. It was observed that the climate lacks trust, operational	2 3 4 5 6 7 8	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the design and to role out improvements FDA-wide. It was recommended that the pilot be designed with an eye toward future expansion. We will discuss
2 3 4 5 6 7 8 9	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the mindsets and behaviors observed at the Agency do not support an effective and efficient hiring process. It was observed that the climate lacks trust, operational discipline, and creativity. Motivation of those	2 3 4 5 6 7 8	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the design and to role out improvements FDA-wide. It was recommended that the pilot be designed with an eye toward future expansion. We will discuss the details of FDA's decision to implement these recommendations and to conduct such a pilot shortly.
2 3 4 5 6 7 8 9	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the mindsets and behaviors observed at the Agency do not support an effective and efficient hiring process. It was observed that the climate lacks trust, operational discipline, and creativity. Motivation of those executing the hiring process is poor without focused	2 3 4 5 6 7 8 9	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the design and to role out improvements FDA-wide. It was recommended that the pilot be designed with an eye toward future expansion. We will discuss the details of FDA's decision to implement these recommendations and to conduct such a pilot shortly.
2 3 4 5 6 7 8 9 10 11	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the mindsets and behaviors observed at the Agency do not support an effective and efficient hiring process. It was observed that the climate lacks trust, operational discipline, and creativity. Motivation of those executing the hiring process is poor without focused leadership, personal ownership, and significant rewards and recognition. External customer orientation is weak towards hiring managers and towards candidates. And	2 3 4 5 6 7 8 9 10	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the design and to role out improvements FDA-wide. It was recommended that the pilot be designed with an eye toward future expansion. We will discuss the details of FDA's decision to implement these recommendations and to conduct such a pilot shortly. Thank you.
2 3 4 5 6 7 8 9 10 11	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the mindsets and behaviors observed at the Agency do not support an effective and efficient hiring process. It was observed that the climate lacks trust, operational discipline, and creativity. Motivation of those executing the hiring process is poor without focused leadership, personal ownership, and significant rewards and recognition. External customer orientation is weak	2 3 4 5 6 7 8 9 10 11 12	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the design and to role out improvements FDA-wide. It was recommended that the pilot be designed with an eye toward future expansion. We will discuss the details of FDA's decision to implement these recommendations and to conduct such a pilot shortly. Thank you. MS. SHERMAN: Thank you, Steve.
2 3 4 5 6 7 8 9 10 11 12	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the mindsets and behaviors observed at the Agency do not support an effective and efficient hiring process. It was observed that the climate lacks trust, operational discipline, and creativity. Motivation of those executing the hiring process is poor without focused leadership, personal ownership, and significant rewards and recognition. External customer orientation is weak towards hiring managers and towards candidates. And	2 3 4 5 6 7 8 9 10 11 12 13	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the design and to role out improvements FDA-wide. It was recommended that the pilot be designed with an eye toward future expansion. We will discuss the details of FDA's decision to implement these recommendations and to conduct such a pilot shortly. Thank you. MS. SHERMAN: Thank you, Steve. Our next two speakers will discuss both the
2 3 4 5 6 7 8 9 10 11 12 13	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the mindsets and behaviors observed at the Agency do not support an effective and efficient hiring process. It was observed that the climate lacks trust, operational discipline, and creativity. Motivation of those executing the hiring process is poor without focused leadership, personal ownership, and significant rewards and recognition. External customer orientation is weak towards hiring managers and towards candidates. And there is unclear direction due to insufficient shared	2 3 4 5 6 7 8 9 10 11 12 13	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the design and to role out improvements FDA-wide. It was recommended that the pilot be designed with an eye toward future expansion. We will discuss the details of FDA's decision to implement these recommendations and to conduct such a pilot shortly. Thank you. MS. SHERMAN: Thank you, Steve. Our next two speakers will discuss both the recent accomplishments with their hiring and provide
2 3 4 5 6 7 8 9 10 11 12 13 14 15	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the mindsets and behaviors observed at the Agency do not support an effective and efficient hiring process. It was observed that the climate lacks trust, operational discipline, and creativity. Motivation of those executing the hiring process is poor without focused leadership, personal ownership, and significant rewards and recognition. External customer orientation is weak towards hiring managers and towards candidates. And there is unclear direction due to insufficient shared vision, accountability, and employee involvement.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the design and to role out improvements FDA-wide. It was recommended that the pilot be designed with an eye toward future expansion. We will discuss the details of FDA's decision to implement these recommendations and to conduct such a pilot shortly. Thank you. MS. SHERMAN: Thank you, Steve. Our next two speakers will discuss both the recent accomplishments with their hiring and provide some more detail about the pilot.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the mindsets and behaviors observed at the Agency do not support an effective and efficient hiring process. It was observed that the climate lacks trust, operational discipline, and creativity. Motivation of those executing the hiring process is poor without focused leadership, personal ownership, and significant rewards and recognition. External customer orientation is weak towards hiring managers and towards candidates. And there is unclear direction due to insufficient shared vision, accountability, and employee involvement. It is important to note that these cultural	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the design and to role out improvements FDA-wide. It was recommended that the pilot be designed with an eye toward future expansion. We will discuss the details of FDA's decision to implement these recommendations and to conduct such a pilot shortly. Thank you. MS. SHERMAN: Thank you, Steve. Our next two speakers will discuss both the recent accomplishments with their hiring and provide some more detail about the pilot. First Tania Tse is FDA's Director of OHR,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the mindsets and behaviors observed at the Agency do not support an effective and efficient hiring process. It was observed that the climate lacks trust, operational discipline, and creativity. Motivation of those executing the hiring process is poor without focused leadership, personal ownership, and significant rewards and recognition. External customer orientation is weak towards hiring managers and towards candidates. And there is unclear direction due to insufficient shared vision, accountability, and employee involvement. It is important to note that these cultural findings are not limited to the Office of Human	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the design and to role out improvements FDA-wide. It was recommended that the pilot be designed with an eye toward future expansion. We will discuss the details of FDA's decision to implement these recommendations and to conduct such a pilot shortly. Thank you. MS. SHERMAN: Thank you, Steve. Our next two speakers will discuss both the recent accomplishments with their hiring and provide some more detail about the pilot. First Tania Tse is FDA's Director of OHR, Office of Human Resources. And as Steve pointed out
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the mindsets and behaviors observed at the Agency do not support an effective and efficient hiring process. It was observed that the climate lacks trust, operational discipline, and creativity. Motivation of those executing the hiring process is poor without focused leadership, personal ownership, and significant rewards and recognition. External customer orientation is weak towards hiring managers and towards candidates. And there is unclear direction due to insufficient shared vision, accountability, and employee involvement. It is important to note that these cultural findings are not limited to the Office of Human Resources but were observed throughout the Agency as	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the design and to role out improvements FDA-wide. It was recommended that the pilot be designed with an eye toward future expansion. We will discuss the details of FDA's decision to implement these recommendations and to conduct such a pilot shortly. Thank you. MS. SHERMAN: Thank you, Steve. Our next two speakers will discuss both the recent accomplishments with their hiring and provide some more detail about the pilot. First Tania Tse is FDA's Director of OHR, Office of Human Resources. And as Steve pointed out several times hiring does not exist alone in the silo
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the mindsets and behaviors observed at the Agency do not support an effective and efficient hiring process. It was observed that the climate lacks trust, operational discipline, and creativity. Motivation of those executing the hiring process is poor without focused leadership, personal ownership, and significant rewards and recognition. External customer orientation is weak towards hiring managers and towards candidates. And there is unclear direction due to insufficient shared vision, accountability, and employee involvement. It is important to note that these cultural findings are not limited to the Office of Human Resources but were observed throughout the Agency as regards to the hiring process. Together all of these root causes drive poor outcomes on timeliness, on accuracy, on employee	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the design and to role out improvements FDA-wide. It was recommended that the pilot be designed with an eye toward future expansion. We will discuss the details of FDA's decision to implement these recommendations and to conduct such a pilot shortly. Thank you. MS. SHERMAN: Thank you, Steve. Our next two speakers will discuss both the recent accomplishments with their hiring and provide some more detail about the pilot. First Tania Tse is FDA's Director of OHR, Office of Human Resources. And as Steve pointed out several times hiring does not exist alone in the silo in OHR but OHR is the place where we've started. And we would not be making the progress that we are making without the full commitment and tireless efforts of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	to achieve. Further without these core metrics performance improvement efforts are rendered extraordinarily difficult. Finally the diagnostic also showed that the mindsets and behaviors observed at the Agency do not support an effective and efficient hiring process. It was observed that the climate lacks trust, operational discipline, and creativity. Motivation of those executing the hiring process is poor without focused leadership, personal ownership, and significant rewards and recognition. External customer orientation is weak towards hiring managers and towards candidates. And there is unclear direction due to insufficient shared vision, accountability, and employee involvement. It is important to note that these cultural findings are not limited to the Office of Human Resources but were observed throughout the Agency as regards to the hiring process. Together all of these root causes drive poor	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	sources of talent, and one that leverages technologies that support meaningful workflow tracking. It was recommended that we evaluate the pilot performance with rigorous metrics and data collection to refine the design and to role out improvements FDA-wide. It was recommended that the pilot be designed with an eye toward future expansion. We will discuss the details of FDA's decision to implement these recommendations and to conduct such a pilot shortly. Thank you. MS. SHERMAN: Thank you, Steve. Our next two speakers will discuss both the recent accomplishments with their hiring and provide some more detail about the pilot. First Tania Tse is FDA's Director of OHR, Office of Human Resources. And as Steve pointed out several times hiring does not exist alone in the silo in OHR but OHR is the place where we've started. And we would not be making the progress that we are making

www.CapitalReportingCompany.com

Daga 19	Page 20
Page 18 1 first with CDER and then she joined OHR in 2012 as	1 intended to support improved hiring including the first
2 Deputy Director and she has been a Director since 2015.	2 six that I will talk a little bit about today. The
3 And she is joined by Melanie Keller who we	3 ones highlighted in blue are the specific PDUFA VI and
4 recruited over the summer into the new position of	4 BsUFA II commitments that we've made.
5 Acting Associate Commissioner for Scientific and	5 So first we'll talk about position based
6 Clinical Recruitment. And falling under her umbrella	6 management. That was a PDUFA VI and BsUFA II
7 is the pilot scientific recruiting team that FDARA	7 commitment. That effort grew out of a need to track
8 hiring authorities which are a crucial tool for us and	8 filled positions and funded vacancies across our Agency
	9 to support planning at the center and office levels,
9 basically innovation and she has assembled what she	10 facilitate consistent information sharing with
10 refers to as hashtag team hiring which seems to be one	11 stakeholders including Congress, our regulated
11 of our most cheerful groups.	12 industries, the trade press, and the public. And
12 So they will now join us.	
13 Thank you.	13 improve our ability to strategically plan for hiring.
14 FDA PDUFA VI and BsUFA II HIRING AND RETENTION PROGRESS	14 The initiative began in 2015 as we worked with our
15 MS. TSE: Good morning. Thank you, Dr.	15 summer partners to manually, I can't tell you how
16 Sherman for that kind introduction. I am pleased to be	16 painful that was, gather and track data on filled and
17 here today to share initiatives underway within the	17 vacant positions to establish a baseline.
18 Office of Human Resources to better support the hiring	18 The project has since evolved to an FDA
19 process and meet the commitments that FDA made to our	19 position tracking system that we developed in house
20 industry partners during the recent PDUFA VI and BsUFA	20 that leverages existing HR databases and financial
21 II negotiations.	21 systems. This new tool is currently being piloted by
22 While it has been received that blains is it	22 one of our smaller centers and is available for other
22 While it has been mentioned that hiring is at	22 one of our smaller centers and is available for other
Page 19	Page 21
Page 19 1 unprecedented levels for our Agency all of us recognize	Page 21 1 centers to pilot as well.
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue.	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year.
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to 7 acknowledge FDA hiring managers, human capital teams	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year. 7 EHCM, I'll share a little bit of information
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to 7 acknowledge FDA hiring managers, human capital teams 8 and HR staff who've worked together to hire more than	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year. 7 EHCM, I'll share a little bit of information 8 about that. While not a specific PDUFA of BsUFA
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to 7 acknowledge FDA hiring managers, human capital teams 8 and HR staff who've worked together to hire more than 9 5400 people since Fiscal Year 2014 including 1100 last	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year. 7 EHCM, I'll share a little bit of information 8 about that. While not a specific PDUFA of BsUFA 9 commitment this project will modernize our core HR
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to 7 acknowledge FDA hiring managers, human capital teams 8 and HR staff who've worked together to hire more than 9 5400 people since Fiscal Year 2014 including 1100 last 10 year alone when the hiring freeze and other limitations	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year. 7 EHCM, I'll share a little bit of information 8 about that. While not a specific PDUFA of BsUFA 9 commitment this project will modernize our core HR 10 system and will include new tools and functionality
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to 7 acknowledge FDA hiring managers, human capital teams 8 and HR staff who've worked together to hire more than 9 5400 people since Fiscal Year 2014 including 1100 last 10 year alone when the hiring freeze and other limitations 11 were in place for most of that year.	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year. 7 EHCM, I'll share a little bit of information 8 about that. While not a specific PDUFA of BsUFA 9 commitment this project will modernize our core HR 10 system and will include new tools and functionality 11 like the position management module that I mentioned
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to 7 acknowledge FDA hiring managers, human capital teams 8 and HR staff who've worked together to hire more than 9 5400 people since Fiscal Year 2014 including 1100 last 10 year alone when the hiring freeze and other limitations 11 were in place for most of that year. 12 And while FDA's attrition rate is low for an	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year. 7 EHCM, I'll share a little bit of information 8 about that. While not a specific PDUFA of BsUFA 9 commitment this project will modernize our core HR 10 system and will include new tools and functionality 11 like the position management module that I mentioned 12 and also offer data analytics to support human capital
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to 7 acknowledge FDA hiring managers, human capital teams 8 and HR staff who've worked together to hire more than 9 5400 people since Fiscal Year 2014 including 1100 last 10 year alone when the hiring freeze and other limitations 11 were in place for most of that year. 12 And while FDA's attrition rate is low for an 13 organization of our size averaging about five to six	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year. 7 EHCM, I'll share a little bit of information 8 about that. While not a specific PDUFA of BsUFA 9 commitment this project will modernize our core HR 10 system and will include new tools and functionality 11 like the position management module that I mentioned 12 and also offer data analytics to support human capital 13 decision making. And you heard data quality and
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to 7 acknowledge FDA hiring managers, human capital teams 8 and HR staff who've worked together to hire more than 9 5400 people since Fiscal Year 2014 including 1100 last 10 year alone when the hiring freeze and other limitations 11 were in place for most of that year. 12 And while FDA's attrition rate is low for an 13 organization of our size averaging about five to six 14 percent annually the loss we experience of skilled	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year. 7 EHCM, I'll share a little bit of information 8 about that. While not a specific PDUFA of BsUFA 9 commitment this project will modernize our core HR 10 system and will include new tools and functionality 11 like the position management module that I mentioned 12 and also offer data analytics to support human capital 13 decision making. And you heard data quality and 14 security, something we can all agree is critical in our
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to 7 acknowledge FDA hiring managers, human capital teams 8 and HR staff who've worked together to hire more than 9 5400 people since Fiscal Year 2014 including 1100 last 10 year alone when the hiring freeze and other limitations 11 were in place for most of that year. 12 And while FDA's attrition rate is low for an 13 organization of our size averaging about five to six 14 percent annually the loss we experience of skilled 15 scientists, medical staff and other regulatory	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year. 7 EHCM, I'll share a little bit of information 8 about that. While not a specific PDUFA of BsUFA 9 commitment this project will modernize our core HR 10 system and will include new tools and functionality 11 like the position management module that I mentioned 12 and also offer data analytics to support human capital 13 decision making. And you heard data quality and 14 security, something we can all agree is critical in our 15 current environment.
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to 7 acknowledge FDA hiring managers, human capital teams 8 and HR staff who've worked together to hire more than 9 5400 people since Fiscal Year 2014 including 1100 last 10 year alone when the hiring freeze and other limitations 11 were in place for most of that year. 12 And while FDA's attrition rate is low for an 13 organization of our size averaging about five to six 14 percent annually the loss we experience of skilled 15 scientists, medical staff and other regulatory 16 professionals is felt across our programs.	 Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year. 7 EHCM, I'll share a little bit of information 8 about that. While not a specific PDUFA of BsUFA 9 commitment this project will modernize our core HR 10 system and will include new tools and functionality 11 like the position management module that I mentioned 12 and also offer data analytics to support human capital 13 decision making. And you heard data quality and 14 security, something we can all agree is critical in our 15 current environment. 16 Position classification this is another one of
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to 7 acknowledge FDA hiring managers, human capital teams 8 and HR staff who've worked together to hire more than 9 5400 people since Fiscal Year 2014 including 1100 last 10 year alone when the hiring freeze and other limitations 11 were in place for most of that year. 12 And while FDA's attrition rate is low for an 13 organization of our size averaging about five to six 14 percent annually the loss we experience of skilled 15 scientists, medical staff and other regulatory 16 professionals is felt across our programs. 17 So let me see if I can figure there we go.	 Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year. 7 EHCM, I'll share a little bit of information 8 about that. While not a specific PDUFA of BsUFA 9 commitment this project will modernize our core HR 10 system and will include new tools and functionality 11 like the position management module that I mentioned 12 and also offer data analytics to support human capital 13 decision making. And you heard data quality and 14 security, something we can all agree is critical in our 15 current environment. 16 Position classification this is another one of 17 our PDUFA commitments was to establish an online
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to 7 acknowledge FDA hiring managers, human capital teams 8 and HR staff who've worked together to hire more than 9 5400 people since Fiscal Year 2014 including 1100 last 10 year alone when the hiring freeze and other limitations 11 were in place for most of that year. 12 And while FDA's attrition rate is low for an 13 organization of our size averaging about five to six 14 percent annually the loss we experience of skilled 15 scientists, medical staff and other regulatory 16 professionals is felt across our programs. 17 So let me see if I can figure there we go. 18 I forgot to get the tutorial. So what is OHR doing to	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year. 7 EHCM, I'll share a little bit of information 8 about that. While not a specific PDUFA of BsUFA 9 commitment this project will modernize our core HR 10 system and will include new tools and functionality 11 like the position management module that I mentioned 12 and also offer data analytics to support human capital 13 decision making. And you heard data quality and 14 security, something we can all agree is critical in our 15 current environment. 16 Position classification this is another one of 17 our PDUFA commitments was to establish an online 18 classification tool as well as a PD library. It
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to 7 acknowledge FDA hiring managers, human capital teams 8 and HR staff who've worked together to hire more than 9 5400 people since Fiscal Year 2014 including 1100 last 10 year alone when the hiring freeze and other limitations 11 were in place for most of that year. 12 And while FDA's attrition rate is low for an 13 organization of our size averaging about five to six 14 percent annually the loss we experience of skilled 15 scientists, medical staff and other regulatory 16 professionals is felt across our programs. 17 So let me see if I can figure there we go. 18 I forgot to get the tutorial. So what is OHR doing to 19 help in partnership with many folks across FDA? In	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year. 7 EHCM, I'll share a little bit of information 8 about that. While not a specific PDUFA of BsUFA 9 commitment this project will modernize our core HR 10 system and will include new tools and functionality 11 like the position management module that I mentioned 12 and also offer data analytics to support human capital 13 decision making. And you heard data quality and 14 security, something we can all agree is critical in our 15 current environment. 16 Position classification this is another one of 17 our PDUFA commitments was to establish an online 18 classification tool as well as a PD library. It 19 continues to be an area where we have significant
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to 7 acknowledge FDA hiring managers, human capital teams 8 and HR staff who've worked together to hire more than 9 5400 people since Fiscal Year 2014 including 1100 last 10 year alone when the hiring freeze and other limitations 11 were in place for most of that year. 12 And while FDA's attrition rate is low for an 13 organization of our size averaging about five to six 14 percent annually the loss we experience of skilled 15 scientists, medical staff and other regulatory 16 professionals is felt across our programs. 17 So let me see if I can figure there we go. 18 I forgot to get the tutorial. So what is OHR doing to 19 help in partnership with many folks across FDA? In 20 addition to participating in this assessment hoping for	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year. 7 EHCM, I'll share a little bit of information 8 about that. While not a specific PDUFA of BsUFA 9 commitment this project will modernize our core HR 10 system and will include new tools and functionality 11 like the position management module that I mentioned 12 and also offer data analytics to support human capital 13 decision making. And you heard data quality and 14 security, something we can all agree is critical in our 15 current environment. 16 Position classification this is another one of 17 our PDUFA commitments was to establish an online 18 classification tool as well as a PD library. It 19 continues to be an area where we have significant 20 opportunities to improve. Rather than establishing a
Page 19 1 unprecedented levels for our Agency all of us recognize 2 it is not enough. Not enough to close the hiring gaps 3 that have existed at our Agency for years. And not 4 enough to keep pace with FDA's growth over the last few 5 years, a trend we expect to continue. 6 In spite of our hiring challenges I do want to 7 acknowledge FDA hiring managers, human capital teams 8 and HR staff who've worked together to hire more than 9 5400 people since Fiscal Year 2014 including 1100 last 10 year alone when the hiring freeze and other limitations 11 were in place for most of that year. 12 And while FDA's attrition rate is low for an 13 organization of our size averaging about five to six 14 percent annually the loss we experience of skilled 15 scientists, medical staff and other regulatory 16 professionals is felt across our programs. 17 So let me see if I can figure there we go. 18 I forgot to get the tutorial. So what is OHR doing to 19 help in partnership with many folks across FDA? In	Page 21 1 centers to pilot as well. 2 The next phase of our effort for position 3 based management will be to leverage a new position 4 management module that will be integrated into our 5 expected new core HR system EHCM that we expect to 6 launch later this year. 7 EHCM, I'll share a little bit of information 8 about that. While not a specific PDUFA of BsUFA 9 commitment this project will modernize our core HR 10 system and will include new tools and functionality 11 like the position management module that I mentioned 12 and also offer data analytics to support human capital 13 decision making. And you heard data quality and 14 security, something we can all agree is critical in our 15 current environment. 16 Position classification this is another one of 17 our PDUFA commitments was to establish an online 18 classification tool as well as a PD library. It 19 continues to be an area where we have significant

	Page 22		Page 24
1	classified PDs that can either be used as is or	1	biologists and microbiologists positions using the
	slightly modified to meet the needs of a hiring office.		corporate approach in the Spring of 2018.
3	Over the last two years we worked with a	3	While not a PDUFA commitment our most
	contractor to organize more than 21,000 hard copy		successful effort to date has been the launch of our
	position descriptions into a useable SharePoint PD		Title-38 support team. That team supports the hiring
	library which now includes 9,000 only 9,842 position		of both medical officers and dentists across our
	descriptions but are searchable, established in a		organization. The Title-38 team manages a ten-business
	various variety of different occupations at multiple		day process from the receipt of a completed package
	grade levels and varying career ladders that are		from hiring program to the issuance of a tentative job
	available for use across the organization.		offer to a selected physician. This new process has
11	The next phase to further improve		reduced hiring times by 80% for these occupations. And
	classification we've spent the last year developing		to date we've hired 117 new physicians using the
	FDA's own eClass system, an online position		streamline process. In addition our Title-38 team
	classification tool to further automate the process.		supports the important work of FDA's physician
	The new took is currently being launched Agency-wide.		compensation and credentialing board who works to
16	This October we began introducing eClass		assure appropriateness and equity in pay across our
17	center by center offering training on the new tool		Agency.
	including a step-by-step eClass process and supporting	18	The final PDUFA commitment that I will talk
	resource materials available to users. This system is	19	about today is awarding a contract and we have actually
20	currently in use by a number of our center partners and	20	completed this effort. On a regular basis FDA has
21	is rolling out to additional organizations through the	21	special hiring initiatives either in support of new or
22	rest of this year as you see here.	22	expanding user fee programs or other special
	Page 23		Page 25
			1 4ge 25
1	Corporate recruitment, another one of our	1	initiatives. And to ensure that we have ready quick
	-		
2	Corporate recruitment, another one of our	2	initiatives. And to ensure that we have ready quick
2 3	Corporate recruitment, another one of our commitments made to our industry partners, that effort	2 3	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a
2 3 4	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission	2 3 4	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That
2 3 4 5	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring	2 3 4 5	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us
2 3 4 5 6	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring basis to provide managers with access to hiring	2 3 4 5	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us ready access to contractors with a wide range of HR
2 3 4 5 6 7	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring basis to provide managers with access to hiring certificates on a predictable schedule. Key goals of	2 3 4 5 6 7	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us ready access to contractors with a wide range of HR skills.
2 3 4 5 6 7 8	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring basis to provide managers with access to hiring certificates on a predictable schedule. Key goals of our corporate recruitment strategy were to reduce time	2 3 4 5 6 7 8	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us ready access to contractors with a wide range of HR skills. Before I close I do want to share a couple of
2 3 4 5 6 7 8 9	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring basis to provide managers with access to hiring certificates on a predictable schedule. Key goals of our corporate recruitment strategy were to reduce time to hire and reduce the burden of having to initiate	2 3 4 5 6 7 8 9	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us ready access to contractors with a wide range of HR skills. Before I close I do want to share a couple of other efforts that were not committed to as part of the
2 3 4 5 6 7 8 9	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring basis to provide managers with access to hiring certificates on a predictable schedule. Key goals of our corporate recruitment strategy were to reduce time to hire and reduce the burden of having to initiate individual recruit actions each time a hiring need is	2 3 4 5 6 7 8 9 10 11	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us ready access to contractors with a wide range of HR skills. Before I close I do want to share a couple of other efforts that were not committed to as part of the PDUFA VI and BsUFA II negotiations but are key to support the efforts that we are working on to improve hiring here at FDA. Our FDA university has also worked
2 3 4 5 6 7 8 9 10 11 12	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring basis to provide managers with access to hiring certificates on a predictable schedule. Key goals of our corporate recruitment strategy were to reduce time to hire and reduce the burden of having to initiate individual recruit actions each time a hiring need is identified. Since 2015 when we began this effort we've launched corporate recruitment strategies for five	2 3 4 5 6 7 8 9 10 11 12	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us ready access to contractors with a wide range of HR skills. Before I close I do want to share a couple of other efforts that were not committed to as part of the PDUFA VI and BsUFA II negotiations but are key to support the efforts that we are working on to improve hiring here at FDA. Our FDA university has also worked to develop a portfolio of workforce planning
2 3 4 5 6 7 8 9 10 11 12 13	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring basis to provide managers with access to hiring certificates on a predictable schedule. Key goals of our corporate recruitment strategy were to reduce time to hire and reduce the burden of having to initiate individual recruit actions each time a hiring need is identified. Since 2015 when we began this effort we've launched corporate recruitment strategies for five different occupations including math stats,	2 3 4 5 6 7 8 9 10 11 12 13	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us ready access to contractors with a wide range of HR skills. Before I close I do want to share a couple of other efforts that were not committed to as part of the PDUFA VI and BsUFA II negotiations but are key to support the efforts that we are working on to improve hiring here at FDA. Our FDA university has also worked to develop a portfolio of workforce planning capabilities available to our centers including
2 3 4 5 6 7 8 9 10 11 12 13 14	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring basis to provide managers with access to hiring certificates on a predictable schedule. Key goals of our corporate recruitment strategy were to reduce time to hire and reduce the burden of having to initiate individual recruit actions each time a hiring need is identified. Since 2015 when we began this effort we've launched corporate recruitment strategies for five different occupations including math stats, statisticians, pharmacologists, toxicologists and	2 3 4 5 6 7 8 9 10 11 12 13 14	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us ready access to contractors with a wide range of HR skills. Before I close I do want to share a couple of other efforts that were not committed to as part of the PDUFA VI and BsUFA II negotiations but are key to support the efforts that we are working on to improve hiring here at FDA. Our FDA university has also worked to develop a portfolio of workforce planning capabilities available to our centers including providing annual center workplace profiles that will
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring basis to provide managers with access to hiring certificates on a predictable schedule. Key goals of our corporate recruitment strategy were to reduce time to hire and reduce the burden of having to initiate individual recruit actions each time a hiring need is identified. Since 2015 when we began this effort we've launched corporate recruitment strategies for five different occupations including math stats, statisticians, pharmacologists, toxicologists and chemists and have successfully used a process to fill a	2 3 4 5 6 7 8 9 10 11 12 13 14 15	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us ready access to contractors with a wide range of HR skills. Before I close I do want to share a couple of other efforts that were not committed to as part of the PDUFA VI and BsUFA II negotiations but are key to support the efforts that we are working on to improve hiring here at FDA. Our FDA university has also worked to develop a portfolio of workforce planning capabilities available to our centers including providing annual center workplace profiles that will help support human capital decision making from a data
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring basis to provide managers with access to hiring certificates on a predictable schedule. Key goals of our corporate recruitment strategy were to reduce time to hire and reduce the burden of having to initiate individual recruit actions each time a hiring need is identified. Since 2015 when we began this effort we've launched corporate recruitment strategies for five different occupations including math stats, statisticians, pharmacologists, toxicologists and chemists and have successfully used a process to fill a number of positions in often hard to fill professions	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us ready access to contractors with a wide range of HR skills. Before I close I do want to share a couple of other efforts that were not committed to as part of the PDUFA VI and BsUFA II negotiations but are key to support the efforts that we are working on to improve hiring here at FDA. Our FDA university has also worked to develop a portfolio of workforce planning capabilities available to our centers including providing annual center workplace profiles that will help support human capital decision making from a data driven place; launched an FDA succession plan focused
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring basis to provide managers with access to hiring certificates on a predictable schedule. Key goals of our corporate recruitment strategy were to reduce time to hire and reduce the burden of having to initiate individual recruit actions each time a hiring need is identified. Since 2015 when we began this effort we've launched corporate recruitment strategies for five different occupations including math stats, statisticians, pharmacologists, toxicologists and chemists and have successfully used a process to fill a number of positions in often hard to fill professions as outlined here.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us ready access to contractors with a wide range of HR skills. Before I close I do want to share a couple of other efforts that were not committed to as part of the PDUFA VI and BsUFA II negotiations but are key to support the efforts that we are working on to improve hiring here at FDA. Our FDA university has also worked to develop a portfolio of workforce planning capabilities available to our centers including providing annual center workplace profiles that will help support human capital decision making from a data driven place; launched an FDA succession plan focused on growing future Agency leaders; and we expanded exit
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring basis to provide managers with access to hiring certificates on a predictable schedule. Key goals of our corporate recruitment strategy were to reduce time to hire and reduce the burden of having to initiate individual recruit actions each time a hiring need is identified. Since 2015 when we began this effort we've launched corporate recruitment strategies for five different occupations including math stats, statisticians, pharmacologists, toxicologists and chemists and have successfully used a process to fill a number of positions in often hard to fill professions as outlined here. We are currently working with our center	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us ready access to contractors with a wide range of HR skills. Before I close I do want to share a couple of other efforts that were not committed to as part of the PDUFA VI and BsUFA II negotiations but are key to support the efforts that we are working on to improve hiring here at FDA. Our FDA university has also worked to develop a portfolio of workforce planning capabilities available to our centers including providing annual center workplace profiles that will help support human capital decision making from a data driven place; launched an FDA succession plan focused on growing future Agency leaders; and we expanded exit survey capacity Agency-wide so that we can share with
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring basis to provide managers with access to hiring certificates on a predictable schedule. Key goals of our corporate recruitment strategy were to reduce time to hire and reduce the burden of having to initiate individual recruit actions each time a hiring need is identified. Since 2015 when we began this effort we've launched corporate recruitment strategies for five different occupations including math stats, statisticians, pharmacologists, toxicologists and chemists and have successfully used a process to fill a number of positions in often hard to fill professions as outlined here. We are currently working with our center partners on the next round of announcements for each of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us ready access to contractors with a wide range of HR skills. Before I close I do want to share a couple of other efforts that were not committed to as part of the PDUFA VI and BsUFA II negotiations but are key to support the efforts that we are working on to improve hiring here at FDA. Our FDA university has also worked to develop a portfolio of workforce planning capabilities available to our centers including providing annual center workplace profiles that will help support human capital decision making from a data driven place; launched an FDA succession plan focused on growing future Agency leaders; and we expanded exit survey capacity Agency-wide so that we can share with our hiring managers and programs the reasons why our
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring basis to provide managers with access to hiring certificates on a predictable schedule. Key goals of our corporate recruitment strategy were to reduce time to hire and reduce the burden of having to initiate individual recruit actions each time a hiring need is identified. Since 2015 when we began this effort we've launched corporate recruitment strategies for five different occupations including math stats, statisticians, pharmacologists, toxicologists and chemists and have successfully used a process to fill a number of positions in often hard to fill professions as outlined here. We are currently working with our center partners on the next round of announcements for each of these five series and new hiring certificates will be	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us ready access to contractors with a wide range of HR skills. Before I close I do want to share a couple of other efforts that were not committed to as part of the PDUFA VI and BsUFA II negotiations but are key to support the efforts that we are working on to improve hiring here at FDA. Our FDA university has also worked to develop a portfolio of workforce planning capabilities available to our centers including providing annual center workplace profiles that will help support human capital decision making from a data driven place; launched an FDA succession plan focused on growing future Agency leaders; and we expanded exit survey capacity Agency-wide so that we can share with our hiring managers and programs the reasons why our staff are making decisions to leave FDA.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Corporate recruitment, another one of our commitments made to our industry partners, that effort was designed to announce commonly filled mission critical positions at the FDA level on a recurring basis to provide managers with access to hiring certificates on a predictable schedule. Key goals of our corporate recruitment strategy were to reduce time to hire and reduce the burden of having to initiate individual recruit actions each time a hiring need is identified. Since 2015 when we began this effort we've launched corporate recruitment strategies for five different occupations including math stats, statisticians, pharmacologists, toxicologists and chemists and have successfully used a process to fill a number of positions in often hard to fill professions as outlined here. We are currently working with our center partners on the next round of announcements for each of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	initiatives. And to ensure that we have ready quick access to needed surge capacity we worked to award a large scale multi-vendor, multi-year contract. That contract was awarded this summer which does provide us ready access to contractors with a wide range of HR skills. Before I close I do want to share a couple of other efforts that were not committed to as part of the PDUFA VI and BsUFA II negotiations but are key to support the efforts that we are working on to improve hiring here at FDA. Our FDA university has also worked to develop a portfolio of workforce planning capabilities available to our centers including providing annual center workplace profiles that will help support human capital decision making from a data driven place; launched an FDA succession plan focused on growing future Agency leaders; and we expanded exit survey capacity Agency-wide so that we can share with our hiring managers and programs the reasons why our

www.CapitalReportingCompany.com

	Page 26		Page 28
1	the service we provide to our customers and our	1	We go to on-campus scientific recruiting
2	commitment to improving how we support the Agency's	2	events. And the other thing that we're working on is
3	public health mission. We look forward to our	3	establishing strategic relationships with academic
	continued partnerships with our FDA centers and offices		institutions and professional associations an ongoing
	and continued engagement with the Office of Medical		manner so that when we are teeing up to recruit for the
	Products and Tobacco as they work to design a modern		corporate recruitment like Tania was speaking about we
	hiring process for the FDA.		can reach out and advertise our positions so that it
8	It is now my pleasure to turn over the podium		coincides with when those vacancies are open.
9	to my colleague, Melanie Keller, who is going to	9	We also believe that targeting on STEM
	provide some additional information on other efforts	10	occupations earlier in individual's careers perhaps in
	under way.		their pharmacy program or different kinds of targeted
12	Thank you.		outreach could also help folks realize FDA is where
13	MS. KELLER: Thank you, Tania. The next PDUFA		they want to work.
	VI and BsUFA II commitment that we'll discuss today is	14	The next commitment is hiring; hiring the
	establishing a staff, we call it the scientific		PDUFA VI and BsUFA II hires. This shows our targeted
	staffing team, that will conduct continuous recruiting		hires for the five-year period of the agreements. To
	and staffing and retention of scientific technical and		date and it is only November we've hired three in CDER,
	professional staff.		seven in CBER for PDUFA VI, and one for BsUFA. And w
19	So in April we established the staff. We've		have a lot of recruitment activity underway.
	recruited 50% of the staff and we plan to achieve 100%	20	We are targeting in the pilot the PDUFA VI and
	by March 2018. And right now we have a national search		BsUFA II hires. So those will be an area of focus and
	underway for the Associate Director for Scientific		I'll share that shortly.
	Page 27		Page 29
	1 age 27		
1	Staffing that will lead that team. The kinds of things	1	
	Staffing that will lead that team. The kinds of things that they are focusing on right now primarily		The last commitment and why you are here was
2	that they are focusing on right now primarily	2	The last commitment and why you are here was to conduct a comprehensive review of the hiring process
2 3	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really	2 3	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our
2 3 4	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media	2 3 4	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and
2 3 4	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on.	2 3 4 5	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment.
2 3 4 5 6	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go	2 3 4 5 6	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can
2 3 4 5 6 7	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go to some of these conferences a lot of people come to	2 3 4 5 6 7	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can check this commitment, not quite as complete because
2 3 4 5 6 7 8	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go to some of these conferences a lot of people come to the table and they are surprised. FDA is hiring? What	2 3 4 5 6 7 8	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can check this commitment, not quite as complete because the docket will remain open until January but we've
2 3 4 5 6 7 8 9	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go to some of these conferences a lot of people come to the table and they are surprised. FDA is hiring? What do you do at FDA? And so we really need to get our	2 3 4 5 6 7 8 9	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can check this commitment, not quite as complete because the docket will remain open until January but we've really focused on this commitment because it really
2 3 4 5 6 7 8 9 10	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go to some of these conferences a lot of people come to the table and they are surprised. FDA is hiring? What do you do at FDA? And so we really need to get our message out that we are recruiting and we are an	2 3 4 5 6 7 8 9	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can check this commitment, not quite as complete because the docket will remain open until January but we've really focused on this commitment because it really provides the baseline for our future.
2 3 4 5 6 7 8 9 10	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go to some of these conferences a lot of people come to the table and they are surprised. FDA is hiring? What do you do at FDA? And so we really need to get our message out that we are recruiting and we are an employer of choice.	2 3 4 5 6 7 8 9 10 11	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can check this commitment, not quite as complete because the docket will remain open until January but we've really focused on this commitment because it really provides the baseline for our future. Below you see outlined future commitment dates
2 3 4 5 6 7 8 9 10 11 12	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go to some of these conferences a lot of people come to the table and they are surprised. FDA is hiring? What do you do at FDA? And so we really need to get our message out that we are recruiting and we are an employer of choice. We have several targeted strategies for how we	2 3 4 5 6 7 8 9 10 11 12	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can check this commitment, not quite as complete because the docket will remain open until January but we've really focused on this commitment because it really provides the baseline for our future.
2 3 4 5 6 7 8 9 10 11 12 13	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go to some of these conferences a lot of people come to the table and they are surprised. FDA is hiring? What do you do at FDA? And so we really need to get our message out that we are recruiting and we are an employer of choice. We have several targeted strategies for how we can outreach and really be more proactive about the way	2 3 4 5 6 7 8 9 10 11 12	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can check this commitment, not quite as complete because the docket will remain open until January but we've really focused on this commitment because it really provides the baseline for our future. Below you see outlined future commitment dates for the subsequent continuous assessment and out- briefs.
2 3 4 5 6 7 8 9 10 11 12 13 14	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go to some of these conferences a lot of people come to the table and they are surprised. FDA is hiring? What do you do at FDA? And so we really need to get our message out that we are recruiting and we are an employer of choice. We have several targeted strategies for how we can outreach and really be more proactive about the way we are identifying staff for our critical positions.	2 3 4 5 6 7 8 9 10 11 12 13 14	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can check this commitment, not quite as complete because the docket will remain open until January but we've really focused on this commitment because it really provides the baseline for our future. Below you see outlined future commitment dates for the subsequent continuous assessment and out- briefs. So that concludes the portion of the meeting
2 3 4 5 6 7 8 9 10 11 12 13 14 15	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go to some of these conferences a lot of people come to the table and they are surprised. FDA is hiring? What do you do at FDA? And so we really need to get our message out that we are recruiting and we are an employer of choice. We have several targeted strategies for how we can outreach and really be more proactive about the way we are identifying staff for our critical positions. One strategy is to establish recruitment ambassadors	2 3 4 5 6 7 8 9 10 11 12 13 14 15	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can check this commitment, not quite as complete because the docket will remain open until January but we've really focused on this commitment because it really provides the baseline for our future. Below you see outlined future commitment dates for the subsequent continuous assessment and out- briefs. So that concludes the portion of the meeting where we update on the PDUFA VI and BsUFA II
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go to some of these conferences a lot of people come to the table and they are surprised. FDA is hiring? What do you do at FDA? And so we really need to get our message out that we are recruiting and we are an employer of choice. We have several targeted strategies for how we can outreach and really be more proactive about the way we are identifying staff for our critical positions. One strategy is to establish recruitment ambassadors throughout the Agency. We have a far reach into	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can check this commitment, not quite as complete because the docket will remain open until January but we've really focused on this commitment because it really provides the baseline for our future. Below you see outlined future commitment dates for the subsequent continuous assessment and out- briefs. So that concludes the portion of the meeting where we update on the PDUFA VI and BsUFA II commitments in progress.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go to some of these conferences a lot of people come to the table and they are surprised. FDA is hiring? What do you do at FDA? And so we really need to get our message out that we are recruiting and we are an employer of choice. We have several targeted strategies for how we can outreach and really be more proactive about the way we are identifying staff for our critical positions. One strategy is to establish recruitment ambassadors throughout the Agency. We have a far reach into industry and academia and professional associations	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can check this commitment, not quite as complete because the docket will remain open until January but we've really focused on this commitment because it really provides the baseline for our future. Below you see outlined future commitment dates for the subsequent continuous assessment and out- briefs. So that concludes the portion of the meeting where we update on the PDUFA VI and BsUFA II commitments in progress. REIMAGINE FDA HIRING PILOT
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go to some of these conferences a lot of people come to the table and they are surprised. FDA is hiring? What do you do at FDA? And so we really need to get our message out that we are recruiting and we are an employer of choice. We have several targeted strategies for how we can outreach and really be more proactive about the way we are identifying staff for our critical positions. One strategy is to establish recruitment ambassadors throughout the Agency. We have a far reach into industry and academia and professional associations with our staff. So having when they go to these	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can check this commitment, not quite as complete because the docket will remain open until January but we've really focused on this commitment because it really provides the baseline for our future. Below you see outlined future commitment dates for the subsequent continuous assessment and out- briefs. So that concludes the portion of the meeting where we update on the PDUFA VI and BsUFA II commitments in progress. REIMAGINE FDA HIRING PILOT MS. KELLER: And now I'd like to move into
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go to some of these conferences a lot of people come to the table and they are surprised. FDA is hiring? What do you do at FDA? And so we really need to get our message out that we are recruiting and we are an employer of choice. We have several targeted strategies for how we can outreach and really be more proactive about the way we are identifying staff for our critical positions. One strategy is to establish recruitment ambassadors throughout the Agency. We have a far reach into industry and academia and professional associations with our staff. So having when they go to these meetings you know donning them as recruitment	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can check this commitment, not quite as complete because the docket will remain open until January but we've really focused on this commitment because it really provides the baseline for our future. Below you see outlined future commitment dates for the subsequent continuous assessment and out- briefs. So that concludes the portion of the meeting where we update on the PDUFA VI and BsUFA II commitments in progress. REIMAGINE FDA HIRING PILOT MS. KELLER: And now I'd like to move into sharing about the FDA reimagined Hiring Pilot. I'll
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go to some of these conferences a lot of people come to the table and they are surprised. FDA is hiring? What do you do at FDA? And so we really need to get our message out that we are recruiting and we are an employer of choice. We have several targeted strategies for how we can outreach and really be more proactive about the way we are identifying staff for our critical positions. One strategy is to establish recruitment ambassadors throughout the Agency. We have a far reach into industry and academia and professional associations with our staff. So having when they go to these meetings you know donning them as recruitment ambassadors providing them training and having part of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can check this commitment, not quite as complete because the docket will remain open until January but we've really focused on this commitment because it really provides the baseline for our future. Below you see outlined future commitment dates for the subsequent continuous assessment and out- briefs. So that concludes the portion of the meeting where we update on the PDUFA VI and BsUFA II commitments in progress. REIMAGINE FDA HIRING PILOT MS. KELLER: And now I'd like to move into sharing about the FDA reimagined Hiring Pilot. I'll provide an overview of the pilot's scope and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	that they are focusing on right now primarily developing an FDA recruitment brand; we don't really have one and using that to deploy through social media strategy that we are working on. I think that when our scientific staffers go to some of these conferences a lot of people come to the table and they are surprised. FDA is hiring? What do you do at FDA? And so we really need to get our message out that we are recruiting and we are an employer of choice. We have several targeted strategies for how we can outreach and really be more proactive about the way we are identifying staff for our critical positions. One strategy is to establish recruitment ambassadors throughout the Agency. We have a far reach into industry and academia and professional associations with our staff. So having when they go to these meetings you know donning them as recruitment	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	The last commitment and why you are here was to conduct a comprehensive review of the hiring process and staffing capacity and capabilities that enable our successes at the Agency. And Steve provided and excellent overview of the initial baseline assessment. The report was published I think after today we can check this commitment, not quite as complete because the docket will remain open until January but we've really focused on this commitment because it really provides the baseline for our future. Below you see outlined future commitment dates for the subsequent continuous assessment and out- briefs. So that concludes the portion of the meeting where we update on the PDUFA VI and BsUFA II commitments in progress. REIMAGINE FDA HIRING PILOT MS. KELLER: And now I'd like to move into sharing about the FDA reimagined Hiring Pilot. I'll

www.CapitalReportingCompany.com

	Page 32
Page 30 1 This is an overview of how the hiring pilot	1 and candidates. We conducted the policy assessment
2 will be run alongside the current state. Several	2 from OPM and we engaged an expert contractor to really
3 positions will be entirely pulled out and dropped into	3 do the complete policy review so we know what the
4 the pilot and run through the new process from start to	4 boundaries are what we have to follow within regulation
5 finish. We expect the pilot to launch in early 2018	5 and then what our flexibilities are within the Agency.
6 and will likely run through the year given the scope.	6 We've engaged a contractor to pressure test
7 Once the endpoints have been reached, scale up	7 our design, conduct external benchmarks from peer
8 and implementation across a broader organization	8 agencies like the National Institutes of Health, the
9 particularly focused in CDER and CBER will begin. And	9 National Oceanic and Atmospheric Administration and
10 then eventually the future state will look like an	10 also an extensive network of external experts in design
11 entirely new engine running the reimagined process for	11 thinking and process excellence.
	12 Very quickly to know we've been making a lot
12 all positions.13 The pilot includes a significant percent of	13 of progress in the pilot design. This is an overview
14 vacancies for both CDER and CBER and within CDER we've	14 of the journey that the team has been on in designing15 and developing the pilot. We kicked off early in
15 been including a range of PDUFA IV commitments and16 mission critical occupations from select offices; the	15 and developing the pilot. We kicked off early in 16 September and expect to begin implementation planning
L · · ·	
17 Office of Strategic Programs, the Office of New Drugs,	17 starting in December which is Friday.
18 and the Office of Surveillance and Epidemiology. From	18 So as you can see we are going to launch that
19 CBER we will be focusing primarily on the PDUFA VI	19 pilot in early 2018 and then with the goal of meeting
20 commitments across all offices.	20 the PDUFA VI and BsUFA II commitment of implementing
21 The team's objectives are rooted in the	21 the findings from the initial report in December of
22 objectives of testing hypothesis early and using the	22 2018.
Page 31	Page 33
1 pilot as a vehicle to make real progress and to act as	1 As I mentioned a minute ago the team routed
2 a testing ground for a process which just doesn't work	2 our approach in insuring we create a process which adds
3 in a vacuum but can be scaled across the organization.	3 value to customers and the customers in this instance
4 The design challenges conventional wisdom and the team	4 are hiring managers and candidates. We come to the
5 has been asking themselves why? So as we go through	5 data that was collected as a part of the diagnostic
6 the process and we're designing it we really question	
	6 which included over six qualitative and quantitative
7 that current state. Why do we do that? Well, why do	7 surveys and over 35 in depth one-on-one interviews with
8 we do that? And really getting to the deeper reasons	7 surveys and over 35 in depth one-on-one interviews with8 new hires and hiring managers to create a typical
8 we do that? And really getting to the deeper reasons9 to uncover if its really necessary or if it can be	7 surveys and over 35 in depth one-on-one interviews with8 new hires and hiring managers to create a typical9 hiring manager and candidate persona.
8 we do that? And really getting to the deeper reasons9 to uncover if its really necessary or if it can be10 changed.	 7 surveys and over 35 in depth one-on-one interviews with 8 new hires and hiring managers to create a typical 9 hiring manager and candidate persona. 10 So we're really taking a look at what the
 8 we do that? And really getting to the deeper reasons 9 to uncover if its really necessary or if it can be 10 changed. 11 One thing we also did is we did an inventory 	 7 surveys and over 35 in depth one-on-one interviews with 8 new hires and hiring managers to create a typical 9 hiring manager and candidate persona. 10 So we're really taking a look at what the 11 customer, the candidate and the hiring manager, needs,
 8 we do that? And really getting to the deeper reasons 9 to uncover if its really necessary or if it can be 10 changed. 11 One thing we also did is we did an inventory 12 of policies, government policies, HHS policies, FDA and 	 7 surveys and over 35 in depth one-on-one interviews with 8 new hires and hiring managers to create a typical 9 hiring manager and candidate persona. 10 So we're really taking a look at what the 11 customer, the candidate and the hiring manager, needs, 12 what motivates them, what success in the hiring process
 8 we do that? And really getting to the deeper reasons 9 to uncover if its really necessary or if it can be 10 changed. 11 One thing we also did is we did an inventory 12 of policies, government policies, HHS policies, FDA and 13 really were able to ask those deeper questions and 	 7 surveys and over 35 in depth one-on-one interviews with 8 new hires and hiring managers to create a typical 9 hiring manager and candidate persona. 10 So we're really taking a look at what the 11 customer, the candidate and the hiring manager, needs, 12 what motivates them, what success in the hiring process 13 looks like. And we've designed the process around that
 8 we do that? And really getting to the deeper reasons 9 to uncover if its really necessary or if it can be 10 changed. 11 One thing we also did is we did an inventory 12 of policies, government policies, HHS policies, FDA and 13 really were able to ask those deeper questions and 14 investigate the assumptions of each step of the process 	 7 surveys and over 35 in depth one-on-one interviews with 8 new hires and hiring managers to create a typical 9 hiring manager and candidate persona. 10 So we're really taking a look at what the 11 customer, the candidate and the hiring manager, needs, 12 what motivates them, what success in the hiring process 13 looks like. And we've designed the process around that 14 and with that in mind. We looked at pain points and
 8 we do that? And really getting to the deeper reasons 9 to uncover if its really necessary or if it can be 10 changed. 11 One thing we also did is we did an inventory 12 of policies, government policies, HHS policies, FDA and 13 really were able to ask those deeper questions and 14 investigate the assumptions of each step of the process 15 that has been designed. 	 7 surveys and over 35 in depth one-on-one interviews with 8 new hires and hiring managers to create a typical 9 hiring manager and candidate persona. 10 So we're really taking a look at what the 11 customer, the candidate and the hiring manager, needs, 12 what motivates them, what success in the hiring process 13 looks like. And we've designed the process around that 14 and with that in mind. We looked at pain points and 15 also points of delight with a goal of having many more
 8 we do that? And really getting to the deeper reasons 9 to uncover if its really necessary or if it can be 10 changed. 11 One thing we also did is we did an inventory 12 of policies, government policies, HHS policies, FDA and 13 really were able to ask those deeper questions and 14 investigate the assumptions of each step of the process 15 that has been designed. 16 Our approach to reimagine the future state 	 7 surveys and over 35 in depth one-on-one interviews with 8 new hires and hiring managers to create a typical 9 hiring manager and candidate persona. 10 So we're really taking a look at what the 11 customer, the candidate and the hiring manager, needs, 12 what motivates them, what success in the hiring process 13 looks like. And we've designed the process around that 14 and with that in mind. We looked at pain points and 15 also points of delight with a goal of having many more 16 points of delight.
 8 we do that? And really getting to the deeper reasons 9 to uncover if its really necessary or if it can be 10 changed. 11 One thing we also did is we did an inventory 12 of policies, government policies, HHS policies, FDA and 13 really were able to ask those deeper questions and 14 investigate the assumptions of each step of the process 15 that has been designed. 16 Our approach to reimagine the future state 17 incorporates multiple sources of insight. So we didn't 	 7 surveys and over 35 in depth one-on-one interviews with 8 new hires and hiring managers to create a typical 9 hiring manager and candidate persona. 10 So we're really taking a look at what the 11 customer, the candidate and the hiring manager, needs, 12 what motivates them, what success in the hiring process 13 looks like. And we've designed the process around that 14 and with that in mind. We looked at pain points and 15 also points of delight with a goal of having many more 16 points of delight. 17 And also governance for implementing the
 8 we do that? And really getting to the deeper reasons 9 to uncover if its really necessary or if it can be 10 changed. 11 One thing we also did is we did an inventory 12 of policies, government policies, HHS policies, FDA and 13 really were able to ask those deeper questions and 14 investigate the assumptions of each step of the process 15 that has been designed. 16 Our approach to reimagine the future state 17 incorporates multiple sources of insight. So we didn't 18 just sit in a room. We included significant data 	 7 surveys and over 35 in depth one-on-one interviews with 8 new hires and hiring managers to create a typical 9 hiring manager and candidate persona. 10 So we're really taking a look at what the 11 customer, the candidate and the hiring manager, needs, 12 what motivates them, what success in the hiring process 13 looks like. And we've designed the process around that 14 and with that in mind. We looked at pain points and 15 also points of delight with a goal of having many more 16 points of delight. 17 And also governance for implementing the 18 recommendations from the assessment was also key. And
 8 we do that? And really getting to the deeper reasons 9 to uncover if its really necessary or if it can be 10 changed. 11 One thing we also did is we did an inventory 12 of policies, government policies, HHS policies, FDA and 13 really were able to ask those deeper questions and 14 investigate the assumptions of each step of the process 15 that has been designed. 16 Our approach to reimagine the future state 17 incorporates multiple sources of insight. So we didn't 18 just sit in a room. We included significant data 19 collection which as you know has been ongoing since 	 7 surveys and over 35 in depth one-on-one interviews with 8 new hires and hiring managers to create a typical 9 hiring manager and candidate persona. 10 So we're really taking a look at what the 11 customer, the candidate and the hiring manager, needs, 12 what motivates them, what success in the hiring process 13 looks like. And we've designed the process around that 14 and with that in mind. We looked at pain points and 15 also points of delight with a goal of having many more 16 points of delight. 17 And also governance for implementing the 18 recommendations from the assessment was also key. And 19 so we have a pilot steering committee which is
 8 we do that? And really getting to the deeper reasons 9 to uncover if its really necessary or if it can be 10 changed. 11 One thing we also did is we did an inventory 12 of policies, government policies, HHS policies, FDA and 13 really were able to ask those deeper questions and 14 investigate the assumptions of each step of the process 15 that has been designed. 16 Our approach to reimagine the future state 17 incorporates multiple sources of insight. So we didn't 18 just sit in a room. We included significant data 19 collection which as you know has been ongoing since 20 2016 and we leveraged all of that data that was 	 7 surveys and over 35 in depth one-on-one interviews with 8 new hires and hiring managers to create a typical 9 hiring manager and candidate persona. 10 So we're really taking a look at what the 11 customer, the candidate and the hiring manager, needs, 12 what motivates them, what success in the hiring process 13 looks like. And we've designed the process around that 14 and with that in mind. We looked at pain points and 15 also points of delight with a goal of having many more 16 points of delight. 17 And also governance for implementing the 18 recommendations from the assessment was also key. And 19 so we have a pilot steering committee which is 20 comprised of the CDER and CBER Center Director, the
 8 we do that? And really getting to the deeper reasons 9 to uncover if its really necessary or if it can be 10 changed. 11 One thing we also did is we did an inventory 12 of policies, government policies, HHS policies, FDA and 13 really were able to ask those deeper questions and 14 investigate the assumptions of each step of the process 15 that has been designed. 16 Our approach to reimagine the future state 17 incorporates multiple sources of insight. So we didn't 18 just sit in a room. We included significant data 19 collection which as you know has been ongoing since 	 7 surveys and over 35 in depth one-on-one interviews with 8 new hires and hiring managers to create a typical 9 hiring manager and candidate persona. 10 So we're really taking a look at what the 11 customer, the candidate and the hiring manager, needs, 12 what motivates them, what success in the hiring process 13 looks like. And we've designed the process around that 14 and with that in mind. We looked at pain points and 15 also points of delight with a goal of having many more 16 points of delight. 17 And also governance for implementing the 18 recommendations from the assessment was also key. And 19 so we have a pilot steering committee which is

	Page 34		Page 36
1	we have the hiring pilot build team. We have contract	1	jobs effectively.
2	support. We have been collaborating very closely with	2	Quality - one thing we heard from the report
3	Tania in the Office of Human Resources, DHHS Office of	3	is that managers need better fitted candidates in the
4	Human Resources. We have SharePoint team,	4	right roles at the right times. That is definitely a
5	communications team. We also found as I mentioned that	5	focus for us.
6	the customer is at the center so we have a customer	6	Customer Service, it is not last, it is not
7	advisory board which is comprised of center executive	7	least. It is most important actually. Hiring managers
8	officers. We've hired our first detailee to lead the	8	that have a designated single point of contact and who
9	pilot operations team, Chantal Dawson. CDER was kind	9	acts as the interface with the HR engine. And then we
10	enough to let her on loan. But we will be in December	10	really are going to be collecting ongoing customer
11	and January populating the pilot operations team	11	service feedback from hiring managers as well.
12	further. And we've also met with various customer,	12	A lot has been considered in how we are going
13	we're calling them customer engagement focus groups,	13	to measure success of the pilot.
14	talking directly to hiring managers.	14	This concludes the overview of the FDA
15	So we have these ideas for the process and	15	reimagined pilot. I really thank you for your
16	then we are sitting down with managers and testing it.	16	attention.
17	Well what do you think of this? Would you like someone	17	We'll now move into a 15-minute break and then
18	from HR to schedule interviews? You know how can we do	o 18	return at ten o'clock.
19	to sort of take care of you in the hiring process to	19	DR. SHERMAN: Can I ask a quick question?
20	reduce the administrative burden.	20	MS. KELLER: Sure.
21	So there is a lot of governance for the pilot	21	DR. SHERMAN: How many people do we have
22	because it is so important and I'm pleased that we have	22	registered to speak? Is there anyone who wants to
	Page 35		Page 37
1	Page 35 such commitment from senior leadership at the Agency.	1	Page 37 speak, who hasn't registered?
1 2	Ũ	1 2	
2	such commitment from senior leadership at the Agency.	2	speak, who hasn't registered?
2 3	such commitment from senior leadership at the Agency. So to have a successful pilot it is really	2 3	speak, who hasn't registered? Okay. In a quest for efficiency and we are
2 3 4	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics	2 3	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the
2 3 4 5	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on	2 3 4	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break?
2 3 4 5	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on those moving forward. And so we are looking at success	2 3 4 5 6	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break? Okay. Let's go to our speaker.
2 3 4 5 6 7	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on those moving forward. And so we are looking at success metrics along five dimensions.	2 3 4 5 6 7	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break? Okay. Let's go to our speaker. MS. SHERMAN: I'm sorry, should I know who
2 3 4 5 6 7 8	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on those moving forward. And so we are looking at success metrics along five dimensions. So timeliness, can we do things in parallel.	2 3 4 5 6 7	 speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break? Okay. Let's go to our speaker. MS. SHERMAN: I'm sorry, should I know who that is? Oh, we were going to get the list during the
2 3 4 5 6 7 8	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on those moving forward. And so we are looking at success metrics along five dimensions. So timeliness, can we do things in parallel. And are we really reducing time in the end-to-end	2 3 4 5 6 7 8 9	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break? Okay. Let's go to our speaker. MS. SHERMAN: I'm sorry, should I know who that is? Oh, we were going to get the list during the break.
2 3 4 5 6 7 8 9 10	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on those moving forward. And so we are looking at success metrics along five dimensions. So timeliness, can we do things in parallel. And are we really reducing time in the end-to-end hiring process, that is top of mind.	2 3 4 5 6 7 8 9 10	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break? Okay. Let's go to our speaker. MS. SHERMAN: I'm sorry, should I know who that is? Oh, we were going to get the list during the break. Jennifer Nowak, could you just identify
2 3 4 5 6 7 8 9 10	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on those moving forward. And so we are looking at success metrics along five dimensions. So timeliness, can we do things in parallel. And are we really reducing time in the end-to-end hiring process, that is top of mind. Accuracy, so ongoing performance process	2 3 4 5 6 7 8 9 10 11	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break? Okay. Let's go to our speaker. MS. SHERMAN: I'm sorry, should I know who that is? Oh, we were going to get the list during the break. Jennifer Nowak, could you just identify yourself and your affiliation please. Thank you. I
2 3 4 5 6 7 8 9 10 11 12	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on those moving forward. And so we are looking at success metrics along five dimensions. So timeliness, can we do things in parallel. And are we really reducing time in the end-to-end hiring process, that is top of mind. Accuracy, so ongoing performance process management. And in the pilot we want to enable as I	2 3 4 5 6 7 8 9 10 11	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break? Okay. Let's go to our speaker. MS. SHERMAN: I'm sorry, should I know who that is? Oh, we were going to get the list during the break. Jennifer Nowak, could you just identify yourself and your affiliation please. Thank you. I think I'm going to get yelled at after the meeting.
2 3 4 5 6 7 8 9 10 11 12 13	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on those moving forward. And so we are looking at success metrics along five dimensions. So timeliness, can we do things in parallel. And are we really reducing time in the end-to-end hiring process, that is top of mind. Accuracy, so ongoing performance process management. And in the pilot we want to enable as I mentioned rapid real-time testing but then also a rapid	2 3 4 5 6 7 8 9 10 11 12 13	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break? Okay. Let's go to our speaker. MS. SHERMAN: I'm sorry, should I know who that is? Oh, we were going to get the list during the break. Jennifer Nowak, could you just identify yourself and your affiliation please. Thank you. I think I'm going to get yelled at after the meeting. PUBLIC COMMENT
2 3 4 5 6 7 8 9 10 11 12 13 14	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on those moving forward. And so we are looking at success metrics along five dimensions. So timeliness, can we do things in parallel. And are we really reducing time in the end-to-end hiring process, that is top of mind. Accuracy, so ongoing performance process management. And in the pilot we want to enable as I mentioned rapid real-time testing but then also a rapid issue escalation. So in the future we never want	2 3 4 5 6 7 8 9 10 11 12 13 14	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break? Okay. Let's go to our speaker. MS. SHERMAN: I'm sorry, should I know who that is? Oh, we were going to get the list during the break. Jennifer Nowak, could you just identify yourself and your affiliation please. Thank you. I think I'm going to get yelled at after the meeting. PUBLIC COMMENT MS. NOWAK: Good morning. My name is
2 3 4 5 6 7 8 9 10 11 12 13 14 15	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on those moving forward. And so we are looking at success metrics along five dimensions. So timeliness, can we do things in parallel. And are we really reducing time in the end-to-end hiring process, that is top of mind. Accuracy, so ongoing performance process management. And in the pilot we want to enable as I mentioned rapid real-time testing but then also a rapid issue escalation. So in the future we never want someone to feel that they have to go to the top of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break? Okay. Let's go to our speaker. MS. SHERMAN: I'm sorry, should I know who that is? Oh, we were going to get the list during the break. Jennifer Nowak, could you just identify yourself and your affiliation please. Thank you. I think I'm going to get yelled at after the meeting. PUBLIC COMMENT MS. NOWAK: Good morning. My name is Jennifer Nowak and I'm speaking today on behalf of the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on those moving forward. And so we are looking at success metrics along five dimensions. So timeliness, can we do things in parallel. And are we really reducing time in the end-to-end hiring process, that is top of mind. Accuracy, so ongoing performance process management. And in the pilot we want to enable as I mentioned rapid real-time testing but then also a rapid issue escalation. So in the future we never want someone to feel that they have to go to the top of the Org Chart to resolve something because the process is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break? Okay. Let's go to our speaker. MS. SHERMAN: I'm sorry, should I know who that is? Oh, we were going to get the list during the break. Jennifer Nowak, could you just identify yourself and your affiliation please. Thank you. I think I'm going to get yelled at after the meeting. PUBLIC COMMENT MS. NOWAK: Good morning. My name is Jennifer Nowak and I'm speaking today on behalf of the Biosimilars Forum. The Biosimilars Forum is a non-
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on those moving forward. And so we are looking at success metrics along five dimensions. So timeliness, can we do things in parallel. And are we really reducing time in the end-to-end hiring process, that is top of mind. Accuracy, so ongoing performance process management. And in the pilot we want to enable as I mentioned rapid real-time testing but then also a rapid issue escalation. So in the future we never want someone to feel that they have to go to the top of the Org Chart to resolve something because the process is being monitored so closely it never has to get to that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break? Okay. Let's go to our speaker. MS. SHERMAN: I'm sorry, should I know who that is? Oh, we were going to get the list during the break. Jennifer Nowak, could you just identify yourself and your affiliation please. Thank you. I think I'm going to get yelled at after the meeting. PUBLIC COMMENT MS. NOWAK: Good morning. My name is Jennifer Nowak and I'm speaking today on behalf of the Biosimilars Forum. The Biosimilars Forum is a non- profit organization whose mission is to advance
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on those moving forward. And so we are looking at success metrics along five dimensions. So timeliness, can we do things in parallel. And are we really reducing time in the end-to-end hiring process, that is top of mind. Accuracy, so ongoing performance process management. And in the pilot we want to enable as I mentioned rapid real-time testing but then also a rapid issue escalation. So in the future we never want someone to feel that they have to go to the top of the Org Chart to resolve something because the process is being monitored so closely it never has to get to that point.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break? Okay. Let's go to our speaker. MS. SHERMAN: I'm sorry, should I know who that is? Oh, we were going to get the list during the break. Jennifer Nowak, could you just identify yourself and your affiliation please. Thank you. I think I'm going to get yelled at after the meeting. PUBLIC COMMENT MS. NOWAK: Good morning. My name is Jennifer Nowak and I'm speaking today on behalf of the Biosimilars Forum. The Biosimilars Forum is a non- profit organization whose mission is to advance biosimilars in the United States with the intent of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on those moving forward. And so we are looking at success metrics along five dimensions. So timeliness, can we do things in parallel. And are we really reducing time in the end-to-end hiring process, that is top of mind. Accuracy, so ongoing performance process management. And in the pilot we want to enable as I mentioned rapid real-time testing but then also a rapid issue escalation. So in the future we never want someone to feel that they have to go to the top of the Org Chart to resolve something because the process is being monitored so closely it never has to get to that point. Employee satisfaction is mentioned; many of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break? Okay. Let's go to our speaker. MS. SHERMAN: I'm sorry, should I know who that is? Oh, we were going to get the list during the break. Jennifer Nowak, could you just identify yourself and your affiliation please. Thank you. I think I'm going to get yelled at after the meeting. PUBLIC COMMENT MS. NOWAK: Good morning. My name is Jennifer Nowak and I'm speaking today on behalf of the Biosimilars Forum. The Biosimilars Forum is a non- profit organization whose mission is to advance biosimilars in the United States with the intent of expanding access and availability of biological
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	such commitment from senior leadership at the Agency. So to have a successful pilot it is really important, I think Steve pointed out, that metrics really have been lacking and we really need to focus on those moving forward. And so we are looking at success metrics along five dimensions. So timeliness, can we do things in parallel. And are we really reducing time in the end-to-end hiring process, that is top of mind. Accuracy, so ongoing performance process management. And in the pilot we want to enable as I mentioned rapid real-time testing but then also a rapid issue escalation. So in the future we never want someone to feel that they have to go to the top of the Org Chart to resolve something because the process is being monitored so closely it never has to get to that point. Employee satisfaction is mentioned; many of the employees involved in the hiring process they need	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	speak, who hasn't registered? Okay. In a quest for efficiency and we are very democratic, how many people would like to skip the break? Okay. Let's go to our speaker. MS. SHERMAN: I'm sorry, should I know who that is? Oh, we were going to get the list during the break. Jennifer Nowak, could you just identify yourself and your affiliation please. Thank you. I think I'm going to get yelled at after the meeting. PUBLIC COMMENT MS. NOWAK: Good morning. My name is Jennifer Nowak and I'm speaking today on behalf of the Biosimilars Forum. The Biosimilars Forum is a non- profit organization whose mission is to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines and improving healthcare.

	Page 38		Page 40
1	market providing more options to patients and	1	report identifies critical gaps and inefficiencies and
2	physicians. The biosimilars forum whose founding	2	sets a baseline upon which to measure improvement
3	members represent the majority of companies with	3	through the duration of BsUFA II and beyond.
4	significant U.S. biosimilars development portfolios was	4	The report's findings are consistent with
5	please to take part in the 2016 negotiations for the	5	concerns voiced during discussions between FDA and
6	biosimilar biological product user fee program or BsUFA	6	industry during the BsUFA II negotiations process. The
7	II the results of which are reflected in the biosimilar	7	gaps and inefficiencies in hiring and retention
8	biological product reauthorization performance goals	8	processes directly impact the capacity and capability
9	and procedures fiscal years 2018 through 2022 which is	9	of the FDA to adequately support the biosimilars
10	commonly called the commitment letter.	10	program. By identifying major root causes and
11	Insuring that the Agency has the manpower and	11	providing recommendations for a path forward the
12	expertise needed to support a robust and efficient	12	initial assessment constitutes a significant first step
13	product review process is critical to the success of	13	towards meeting the BsUFA II hiring and retention
14	biosimilars in the marketplace and was a key	14	commitments.
15	consideration during recent user fee negotiations	15	The Forum understands that staffing of the
16	between FDA and stakeholders.	16	biosimilars review program continues to be a challenge
17	As reflected in the commitment letter the FDA	17	and urges the FDA to continue this forward momentum
18	and industry negotiators agreed to implement changes to	18	with all deliberate speed. The Forum appreciates the
19	the review program for biosimilars which will improve	19	efforts made by the Agency and its continuing
20	communications between biosimilar product sponsors and	20	implementation of the biosimilars program.
21	the FDA and increase the level of transparency	21	We look forward to continued collaboration and
22	associated with the review process. A key feature of	22	respectful working relationship with the FDA.
	Page 39		Page 41
1	Page 39 this program enhancement is FDA's commitment to hire an	1	Page 41 Thank you.
	-	1 2	-
2	this program enhancement is FDA's commitment to hire an		Thank you.
2	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review	2	Thank you. DR. SHERMAN: Thank you for your comments.
2 3 4	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II.	2 3 4	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment.
2 3 4 5	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also	2 3 4 5	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very
2 3 4 5 6	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also pledged to fill a large number of positions before the	2 3 4 5	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very excited OSP is my office so we are in the pilot. It is
2 3 4 5 6 7	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also pledged to fill a large number of positions before the start of BsUFA II to support the biosimilars review	2 3 4 5 6 7	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very excited OSP is my office so we are in the pilot. It is very exciting.
2 3 4 5 6 7	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also pledged to fill a large number of positions before the start of BsUFA II to support the biosimilars review program, an effort which was to be funded from carry-	2 3 4 5 6 7 8	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very excited OSP is my office so we are in the pilot. It is very exciting. So I have a question or just maybe you could
2 3 4 5 6 7 8 9	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also pledged to fill a large number of positions before the start of BsUFA II to support the biosimilars review program, an effort which was to be funded from carry- over fees that had not been expended under BsUFA I.	2 3 4 5 6 7 8 9	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very excited OSP is my office so we are in the pilot. It is very exciting. So I have a question or just maybe you could say more about it. I mean one of the things and as I
2 3 4 5 6 7 8 9 10	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also pledged to fill a large number of positions before the start of BsUFA II to support the biosimilars review program, an effort which was to be funded from carry- over fees that had not been expended under BsUFA I. Further the Agency agreed to set clear hiring	2 3 4 5 6 7 8 9 10	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very excited OSP is my office so we are in the pilot. It is very exciting. So I have a question or just maybe you could say more about it. I mean one of the things and as I looked at the slide I think Tania presented on
2 3 4 5 6 7 8 9 10 11	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also pledged to fill a large number of positions before the start of BsUFA II to support the biosimilars review program, an effort which was to be funded from carry- over fees that had not been expended under BsUFA I. Further the Agency agreed to set clear hiring goals and to complete the establishment of a new	2 3 4 5 6 7 8 9 10 11	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very excited OSP is my office so we are in the pilot. It is very exciting. So I have a question or just maybe you could say more about it. I mean one of the things and as I looked at the slide I think Tania presented on corporate recruiting and the various non-MD, non-
2 3 4 5 6 7 8 9 10 11 12	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also pledged to fill a large number of positions before the start of BsUFA II to support the biosimilars review program, an effort which was to be funded from carry- over fees that had not been expended under BsUFA I. Further the Agency agreed to set clear hiring goals and to complete the establishment of a new dedicated unit within the office of medical products	2 3 4 5 6 7 8 9 10 11 12	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very excited OSP is my office so we are in the pilot. It is very exciting. So I have a question or just maybe you could say more about it. I mean one of the things and as I looked at the slide I think Tania presented on corporate recruiting and the various non-MD, non- Dentist disciplines that are there. And it is great
2 3 4 5 6 7 8 9 10 11 12 13	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also pledged to fill a large number of positions before the start of BsUFA II to support the biosimilars review program, an effort which was to be funded from carry- over fees that had not been expended under BsUFA I. Further the Agency agreed to set clear hiring goals and to complete the establishment of a new dedicated unit within the office of medical products and tobacco. This unit will be charged with the	2 3 4 5 6 7 8 9 10 11 12 13	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very excited OSP is my office so we are in the pilot. It is very exciting. So I have a question or just maybe you could say more about it. I mean one of the things and as I looked at the slide I think Tania presented on corporate recruiting and the various non-MD, non- Dentist disciplines that are there. And it is great that those are going to be undergoing corporate
2 3 4 5 6 7 8 9 10 11 12 13 14	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also pledged to fill a large number of positions before the start of BsUFA II to support the biosimilars review program, an effort which was to be funded from carry- over fees that had not been expended under BsUFA I. Further the Agency agreed to set clear hiring goals and to complete the establishment of a new dedicated unit within the office of medical products and tobacco. This unit will be charged with the continuous recruiting, staffing and retention of	2 3 4 5 6 7 8 9 10 11 12 13 14 15	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very excited OSP is my office so we are in the pilot. It is very exciting. So I have a question or just maybe you could say more about it. I mean one of the things and as I looked at the slide I think Tania presented on corporate recruiting and the various non-MD, non- Dentist disciplines that are there. And it is great that those are going to be undergoing corporate recruiting. And I wonder if you can say more about another dimension of this which is a challenge for us because these are very competitive fields. What can we
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also pledged to fill a large number of positions before the start of BsUFA II to support the biosimilars review program, an effort which was to be funded from carry- over fees that had not been expended under BsUFA I. Further the Agency agreed to set clear hiring goals and to complete the establishment of a new dedicated unit within the office of medical products and tobacco. This unit will be charged with the continuous recruiting, staffing and retention of scientific and technical staff for the review of products under PDUFA and BsUFA in order to ensure that the FDA is staffed with the talent required to keep	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very excited OSP is my office so we are in the pilot. It is very exciting. So I have a question or just maybe you could say more about it. I mean one of the things and as I looked at the slide I think Tania presented on corporate recruiting and the various non-MD, non- Dentist disciplines that are there. And it is great that those are going to be undergoing corporate recruiting. And I wonder if you can say more about another dimension of this which is a challenge for us because these are very competitive fields. What can we do? Do we have any flexibilities with the starting
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also pledged to fill a large number of positions before the start of BsUFA II to support the biosimilars review program, an effort which was to be funded from carry- over fees that had not been expended under BsUFA I. Further the Agency agreed to set clear hiring goals and to complete the establishment of a new dedicated unit within the office of medical products and tobacco. This unit will be charged with the continuous recruiting, staffing and retention of scientific and technical staff for the review of products under PDUFA and BsUFA in order to ensure that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very excited OSP is my office so we are in the pilot. It is very exciting. So I have a question or just maybe you could say more about it. I mean one of the things and as I looked at the slide I think Tania presented on corporate recruiting and the various non-MD, non- Dentist disciplines that are there. And it is great that those are going to be undergoing corporate recruiting. And I wonder if you can say more about another dimension of this which is a challenge for us because these are very competitive fields. What can we
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also pledged to fill a large number of positions before the start of BsUFA II to support the biosimilars review program, an effort which was to be funded from carry- over fees that had not been expended under BsUFA I. Further the Agency agreed to set clear hiring goals and to complete the establishment of a new dedicated unit within the office of medical products and tobacco. This unit will be charged with the continuous recruiting, staffing and retention of scientific and technical staff for the review of products under PDUFA and BsUFA in order to ensure that the FDA is staffed with the talent required to keep	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very excited OSP is my office so we are in the pilot. It is very exciting. So I have a question or just maybe you could say more about it. I mean one of the things and as I looked at the slide I think Tania presented on corporate recruiting and the various non-MD, non- Dentist disciplines that are there. And it is great that those are going to be undergoing corporate recruiting. And I wonder if you can say more about another dimension of this which is a challenge for us because these are very competitive fields. What can we do? Do we have any flexibilities with the starting salaries, what we can offer people to be competitive because there is a lot of competition? The drug
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also pledged to fill a large number of positions before the start of BsUFA II to support the biosimilars review program, an effort which was to be funded from carry- over fees that had not been expended under BsUFA I. Further the Agency agreed to set clear hiring goals and to complete the establishment of a new dedicated unit within the office of medical products and tobacco. This unit will be charged with the continuous recruiting, staffing and retention of scientific and technical staff for the review of products under PDUFA and BsUFA in order to ensure that the FDA is staffed with the talent required to keep pace with rapid innovations and the development of new therapies. The forum applauds the FDA's fulfillment of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very excited OSP is my office so we are in the pilot. It is very exciting. So I have a question or just maybe you could say more about it. I mean one of the things and as I looked at the slide I think Tania presented on corporate recruiting and the various non-MD, non- Dentist disciplines that are there. And it is great that those are going to be undergoing corporate recruiting. And I wonder if you can say more about another dimension of this which is a challenge for us because these are very competitive fields. What can we do? Do we have any flexibilities with the starting salaries, what we can offer people to be competitive because there is a lot of competition? The drug industry represented by our colleagues here are non-
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also pledged to fill a large number of positions before the start of BsUFA II to support the biosimilars review program, an effort which was to be funded from carry- over fees that had not been expended under BsUFA I. Further the Agency agreed to set clear hiring goals and to complete the establishment of a new dedicated unit within the office of medical products and tobacco. This unit will be charged with the continuous recruiting, staffing and retention of scientific and technical staff for the review of products under PDUFA and BsUFA in order to ensure that the FDA is staffed with the talent required to keep pace with rapid innovations and the development of new therapies. The forum applauds the FDA's fulfillment of its commitment to publish an initial assessment report	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very excited OSP is my office so we are in the pilot. It is very exciting. So I have a question or just maybe you could say more about it. I mean one of the things and as I looked at the slide I think Tania presented on corporate recruiting and the various non-MD, non- Dentist disciplines that are there. And it is great that those are going to be undergoing corporate recruiting. And I wonder if you can say more about another dimension of this which is a challenge for us because these are very competitive fields. What can we do? Do we have any flexibilities with the starting salaries, what we can offer people to be competitive because there is a lot of competition? The drug industry represented by our colleagues here are non- slackers when it comes to offering nice packages to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	this program enhancement is FDA's commitment to hire an additional 15 FTEs to support the biosimilars review program within the first year of BsUFA II. During the negotiations process FDA also pledged to fill a large number of positions before the start of BsUFA II to support the biosimilars review program, an effort which was to be funded from carry- over fees that had not been expended under BsUFA I. Further the Agency agreed to set clear hiring goals and to complete the establishment of a new dedicated unit within the office of medical products and tobacco. This unit will be charged with the continuous recruiting, staffing and retention of scientific and technical staff for the review of products under PDUFA and BsUFA in order to ensure that the FDA is staffed with the talent required to keep pace with rapid innovations and the development of new therapies. The forum applauds the FDA's fulfillment of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Thank you. DR. SHERMAN: Thank you for your comments. I believe Dr. Mullin has a comment. DR. MULLIN: So thank you for the I'm very excited OSP is my office so we are in the pilot. It is very exciting. So I have a question or just maybe you could say more about it. I mean one of the things and as I looked at the slide I think Tania presented on corporate recruiting and the various non-MD, non- Dentist disciplines that are there. And it is great that those are going to be undergoing corporate recruiting. And I wonder if you can say more about another dimension of this which is a challenge for us because these are very competitive fields. What can we do? Do we have any flexibilities with the starting salaries, what we can offer people to be competitive because there is a lot of competition? The drug industry represented by our colleagues here are non-

www.CapitalReportingCompany.com

	Page 42		Page 44
1	mind to try to do something with salaries, either both	1	imperative that we continue to work as a team as well
	in the recruiting phase and retention which is quite		as with our external partners who are gathered here
3	critical and part of that office as well, that	3	today and our internal partners.
4	scientific staffing office is to look at the market and	4	As Melanie said the 21st Century Cures
5	the salaries. Can you say more about what we might be	5	addressing Dr. Theresa Mullin's question is important
6	able to do there? What you might be looking at?	6	to FDA. That will avail itself the opportunity to
7	MS. TSE: Absolutely. Melanie and I will tag	7	retain some of our very good people and also make sure
8	team that response. So under current government	8	that we offer competitive packages because some of you
	regulations we have some tools that give us some	9	in here are cherry picking some of our best staff too.
10	limited flexibility that we leverage frequently.	10	So we need to be able to retain our people to be able
11	Something called above the minimum appointment. But	11	to do and be forthright with the FDA mission and vision
12	that is not enough for some of these very tough	12	which are Dr. Gottleib is on the Hill fighting for us
13	scientific positions and helping us fill those. So	13	every day.
14	while we're currently leveraging tools available to us	14	So I want to thank you and as well as thank
	as well as offering retention allowances for those very	15	Dr. Rachel Sherman for sponsoring this.
	key positions, the Cures initiative will really help us	16	Thank you.
	on the compensation level. And Melanie is leading that	17	DR. SHERMAN: Thank you. And Dr. Gottleib
	effort as well. So I will punt the rest of that to	18	would have been here but he's actually on the hill
	her.		testifying. So that dragged him away.
20	MS. KELLER: Thanks, Tania. So I agree I	20	Any other comments or questions.
21	think we're really excited and working feverishly	21	Well, first on behalf of everyone we'd like to
	behind the scenes on implementing the hiring provisions	22	thank you for coming, spending the time this morning.
		-	
	Page 43		Page 45
1	Page 43 of 21st Century Cures and that was enacted in January	1	Page 45 We look forward to comments into the docket.
	ç	-	
2	of 21st Century Cures and that was enacted in January	2	We look forward to comments into the docket.
2 3	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start	23	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as
2 3 4	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay	23	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to
2 3 4 5	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to	2 3 4 5	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together.
2 3 4 5 6	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that.	2 3 4 5 6	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that
2 3 4 5 6 7	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that. So but we are excited that we really have contracted	2 3 4 5 6 7	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that were just made. There's really no higher priority and
2 3 4 5 6 7 8	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that. So but we are excited that we really have contracted with experts to build that new pay structure. And I	2 3 4 5 6 7 8	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that were just made. There's really no higher priority and we are taking this very seriously. We are very
2 3 4 5 6 7 8 9	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that. So but we are excited that we really have contracted with experts to build that new pay structure. And I think the kinds of occupation that you are referring to	2 3 4 5 6 7 8 9	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that were just made. There's really no higher priority and we are taking this very seriously. We are very appreciative of the authorities or nudges whatever and
2 3 4 5 6 7 8 9	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that. So but we are excited that we really have contracted with experts to build that new pay structure. And I think the kinds of occupation that you are referring to Theresa are very in in line with the authorities that	2 3 4 5 6 7 8 9 10	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that were just made. There's really no higher priority and we are taking this very seriously. We are very appreciative of the authorities or nudges whatever and the resources that were provided by the user fee
2 3 4 5 6 7 8 9 10 11	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that. So but we are excited that we really have contracted with experts to build that new pay structure. And I think the kinds of occupation that you are referring to Theresa are very in in line with the authorities that are granted in Cures and can be used in a targeted way.	2 3 4 5 6 7 8 9 10 11	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that were just made. There's really no higher priority and we are taking this very seriously. We are very appreciative of the authorities or nudges whatever and the resources that were provided by the user fee agreements. That gives us a tremendous platform to work
2 3 4 5 6 7 8 9 10 11 12	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that. So but we are excited that we really have contracted with experts to build that new pay structure. And I think the kinds of occupation that you are referring to Theresa are very in in line with the authorities that are granted in Cures and can be used in a targeted way. DR. SHERMAN: I see our Deputy Chief Operating	2 3 4 5 6 7 8 9 10 11 12	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that were just made. There's really no higher priority and we are taking this very seriously. We are very appreciative of the authorities or nudges whatever and the resources that were provided by the user fee agreements. That gives us a tremendous platform to work with. And we have every intention of changing that 12%
2 3 4 5 6 7 8 9 10 11 12	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that. So but we are excited that we really have contracted with experts to build that new pay structure. And I think the kinds of occupation that you are referring to Theresa are very in in line with the authorities that are granted in Cures and can be used in a targeted way. DR. SHERMAN: I see our Deputy Chief Operating Officer; would you like to say anything?	2 3 4 5 6 7 8 9 10 11 12 13	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that were just made. There's really no higher priority and we are taking this very seriously. We are very appreciative of the authorities or nudges whatever and the resources that were provided by the user fee agreements. That gives us a tremendous platform to work with. And we have every intention of changing that 12% flipping it around, maybe we will make it to 100
2 3 4 5 6 7 8 9 10 11 12 13 14	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that. So but we are excited that we really have contracted with experts to build that new pay structure. And I think the kinds of occupation that you are referring to Theresa are very in in line with the authorities that are granted in Cures and can be used in a targeted way. DR. SHERMAN: I see our Deputy Chief Operating Officer; would you like to say anything? CLOSING	2 3 4 5 6 7 8 9 10 11 12 13 14	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that were just made. There's really no higher priority and we are taking this very seriously. We are very appreciative of the authorities or nudges whatever and the resources that were provided by the user fee agreements. That gives us a tremendous platform to work with. And we have every intention of changing that 12% flipping it around, maybe we will make it to 100 satisfy hiring managers. But we are going to do our
2 3 4 5 6 7 8 9 10 11 12 13 14 15	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that. So but we are excited that we really have contracted with experts to build that new pay structure. And I think the kinds of occupation that you are referring to Theresa are very in in line with the authorities that are granted in Cures and can be used in a targeted way. DR. SHERMAN: I see our Deputy Chief Operating Officer; would you like to say anything? CLOSING MS. HEBERT: Hi, good morning everyone. My	2 3 4 5 6 7 8 9 10 11 12 13 14 15	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that were just made. There's really no higher priority and we are taking this very seriously. We are very appreciative of the authorities or nudges whatever and the resources that were provided by the user fee agreements. That gives us a tremendous platform to work with. And we have every intention of changing that 12% flipping it around, maybe we will make it to 100 satisfy hiring managers. But we are going to do our best. I think that this was just pointed out coupled
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that. So but we are excited that we really have contracted with experts to build that new pay structure. And I think the kinds of occupation that you are referring to Theresa are very in in line with the authorities that are granted in Cures and can be used in a targeted way. DR. SHERMAN: I see our Deputy Chief Operating Officer; would you like to say anything? CLOSING MS. HEBERT: Hi, good morning everyone. My name is Angel Hebert and as our fearless leader Dr.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that were just made. There's really no higher priority and we are taking this very seriously. We are very appreciative of the authorities or nudges whatever and the resources that were provided by the user fee agreements. That gives us a tremendous platform to work with. And we have every intention of changing that 12% flipping it around, maybe we will make it to 100 satisfy hiring managers. But we are going to do our best. I think that this was just pointed out coupled with the FDARA or the Cures hiring authorities really
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that. So but we are excited that we really have contracted with experts to build that new pay structure. And I think the kinds of occupation that you are referring to Theresa are very in in line with the authorities that are granted in Cures and can be used in a targeted way. DR. SHERMAN: I see our Deputy Chief Operating Officer; would you like to say anything? CLOSING MS. HEBERT: Hi, good morning everyone. My name is Angel Hebert and as our fearless leader Dr. Rachel Sherman pointed out I am the Deputy Chief	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that were just made. There's really no higher priority and we are taking this very seriously. We are very appreciative of the authorities or nudges whatever and the resources that were provided by the user fee agreements. That gives us a tremendous platform to work with. And we have every intention of changing that 12% flipping it around, maybe we will make it to 100 satisfy hiring managers. But we are going to do our best. I think that this was just pointed out coupled with the FDARA or the Cures hiring authorities really can change the paradigm our hiring.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that. So but we are excited that we really have contracted with experts to build that new pay structure. And I think the kinds of occupation that you are referring to Theresa are very in in line with the authorities that are granted in Cures and can be used in a targeted way. DR. SHERMAN: I see our Deputy Chief Operating Officer; would you like to say anything? CLOSING MS. HEBERT: Hi, good morning everyone. My name is Angel Hebert and as our fearless leader Dr. Rachel Sherman pointed out I am the Deputy Chief Operating Officer who is very glad to be here this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that were just made. There's really no higher priority and we are taking this very seriously. We are very appreciative of the authorities or nudges whatever and the resources that were provided by the user fee agreements. That gives us a tremendous platform to work with. And we have every intention of changing that 12% flipping it around, maybe we will make it to 100 satisfy hiring managers. But we are going to do our best. I think that this was just pointed out coupled with the FDARA or the Cures hiring authorities really can change the paradigm our hiring. This is a great place to work. And we want to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that. So but we are excited that we really have contracted with experts to build that new pay structure. And I think the kinds of occupation that you are referring to Theresa are very in in line with the authorities that are granted in Cures and can be used in a targeted way. DR. SHERMAN: I see our Deputy Chief Operating Officer; would you like to say anything? CLOSING MS. HEBERT: Hi, good morning everyone. My name is Angel Hebert and as our fearless leader Dr. Rachel Sherman pointed out I am the Deputy Chief Operating Officer who is very glad to be here this morning. Fortunately a meeting got cancelled and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that were just made. There's really no higher priority and we are taking this very seriously. We are very appreciative of the authorities or nudges whatever and the resources that were provided by the user fee agreements. That gives us a tremendous platform to work with. And we have every intention of changing that 12% flipping it around, maybe we will make it to 100 satisfy hiring managers. But we are going to do our best. I think that this was just pointed out coupled with the FDARA or the Cures hiring authorities really can change the paradigm our hiring. This is a great place to work. And we want to continue to recruit and retain the best. And I think
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that. So but we are excited that we really have contracted with experts to build that new pay structure. And I think the kinds of occupation that you are referring to Theresa are very in in line with the authorities that are granted in Cures and can be used in a targeted way. DR. SHERMAN: I see our Deputy Chief Operating Officer; would you like to say anything? CLOSING MS. HEBERT: Hi, good morning everyone. My name is Angel Hebert and as our fearless leader Dr. Rachel Sherman pointed out I am the Deputy Chief Operating Officer who is very glad to be here this morning. Fortunately a meeting got cancelled and fortunately I was able to come.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that were just made. There's really no higher priority and we are taking this very seriously. We are very appreciative of the authorities or nudges whatever and the resources that were provided by the user fee agreements. That gives us a tremendous platform to work with. And we have every intention of changing that 12% flipping it around, maybe we will make it to 100 satisfy hiring managers. But we are going to do our best. I think that this was just pointed out coupled with the FDARA or the Cures hiring authorities really can change the paradigm our hiring. This is a great place to work. And we want to continue to recruit and retain the best. And I think Melanie's two plus decades in government are paying
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	of 21st Century Cures and that was enacted in January and I think very soon we'll be able to start implementation of those additional hiring and pay flexibilities. That Act enables the commissioner to set pay up to \$400,000, but not everyone can make that. So but we are excited that we really have contracted with experts to build that new pay structure. And I think the kinds of occupation that you are referring to Theresa are very in in line with the authorities that are granted in Cures and can be used in a targeted way. DR. SHERMAN: I see our Deputy Chief Operating Officer; would you like to say anything? CLOSING MS. HEBERT: Hi, good morning everyone. My name is Angel Hebert and as our fearless leader Dr. Rachel Sherman pointed out I am the Deputy Chief Operating Officer who is very glad to be here this morning. Fortunately a meeting got cancelled and fortunately I was able to come. I want to thank Melanie as well as Tania Tse	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	We look forward to comments into the docket. I'd like to acknowledge first team hiring that or as Melanie dubbed it hashtag team hiring for working to put this meeting together. I'd like to emphasize a couple of points that were just made. There's really no higher priority and we are taking this very seriously. We are very appreciative of the authorities or nudges whatever and the resources that were provided by the user fee agreements. That gives us a tremendous platform to work with. And we have every intention of changing that 12% flipping it around, maybe we will make it to 100 satisfy hiring managers. But we are going to do our best. I think that this was just pointed out coupled with the FDARA or the Cures hiring authorities really can change the paradigm our hiring. This is a great place to work. And we want to continue to recruit and retain the best. And I think Melanie's two plus decades in government are paying off, again we appreciate CDER sending her to us and

	Page 46		Page 48
1	never thought I'd use those two words in a sentence	1	CERTIFICATE OF TRANSCRIBER
2	together but I do it a lot now.	2	I, CHERYL LaSELLE, do hereby certify that this
3	So please look forward to additional updates	3	transcript was prepared from audio to the best of my
4	from us in the future and please send your comments to	4	ability.
5	the docket.	5	
6	And have a good afternoon or actually morning.	6	I am neither counsel for, related to, nor
7	Take care.	7	employed by any of the parties to this action, nor
8	[APPLAUSE.]	8	financially or otherwise interested in the outcome of
9	(WHEREUPON, the Assessment Meeting was	9	this action.
10	concluded.	10	
11		11	
12		12	12/4/2017
13		13	DATE CHERYL LaSELLE
14		14	
15		15	
16		16	
17		17	
18		18	
19		19	
20		20	
21		21	
22		22	
	Page 47		
1	CERTIFICATE OF NOTARY PUBLIC		
2	I, IRENE GRAY, the officer before whom the		
3	foregoing proceeding was taken, do hereby certify that		
4	the proceedings were recorded by me and thereafter		
5	reduced to typewriting under my direction; that said		
6	proceedings are a true and accurate record to the best		
7	of my knowledge, skills, and ability; that I am neither		
8	counsel for, related to, nor employed by any of the		
9	parties to the action in which this was taken; and,		
10	further, that I am not a relative or employee of any		
11	counsel or attorney employed by the parties hereto, nor		
12	financially or otherwise interested in the outcome of		
13	this action.		
14			
15	December 12, 2017		
16			
17	IRENE GRAY		
18	Notary Public in and for the		
19	State of Maryland		
20			
21			
22			

[& - asking]

November 30, 2017

&	4	acknowledge 19:7	agree 21:14 42:20
		45:2	agreed 38:18 39:9
& 1:2,9 3:7	4 3:4	act 8:19 31:1 43:4	agreements 28:16
1	400,000 43:5	acting 2:5 18:5	45:10
100 26:20 45:12	43 3:14	action 47:9,13	allowances 42:15
10903 1:11	5	48:7,9	alongside 30:2
1100 19:9	50 26:20	actions 23:9	amazingly 6:15
117 24:12	5400 19:9	activities 8:13	ambassadors
12 11:7 45:11	550 10:22	activity 28:19	27:15,20
47:15	6	acts 36:9	amount 9:16 10:1
12/4/2017 48:12	600 16:15	addition 5:18	analysis 10:14
140 13:20	7	19:20 24:13 41:22	16:20
15 11:3 36:17 39:2		additional 14:12	analyst 2:4 7:5
18 3:8	7 3:6	22:21 26:10 39:2	analytics 21:12
2	8	43:3 46:3	angel 2:8 3:14
200 16:16	80 24:11	additions 14:3	43:15
2012 18:1	9	addresses 16:9	announce 23:3,22
2014 19:9	9,000 22:6	addressing 44:5	announcements
2015 18:2 20:14	9,842 22:6	adds 33:2	23:19
23:11	9:00 1:6	adequate 35:21	annual 25:14
2016 10:13 31:20		adequately 40:9	annually 19:14
38:5	a	administration	applauds 39:19
2017 1:5 8:19	a.m. 1:6	1:2,9 8:16 32:9	applause 46:8
39:21 47:15	ability 16:10	administrative	appointment
2018 23:21 24:2	20:13 47:7 48:4	34:20	42:11
26:21 30:5 32:19	able 4:20 7:2	advance 37:16	appreciate 5:7
32:22 38:9	31:13 42:6 43:2	advantage 6:18	6:16 45:20
2022 38:9	43:19 44:10,10	advertise 28:7	appreciates 40:18
20993 1:12	absolutely 42:7	advisory 34:7	appreciative 5:2
21,000 22:4	academia 27:17 academic 28:3	affiliation 37:10	45:8
21st 43:1 44:4		afternoon 46:6	approach 24:2
26 3:9	access 23:5 25:2,5 37:18	agencies 11:4 32:8 agency 6:11 8:9	29:21 31:16 33:2
29 3:11		8:19 9:1 10:16	approaching 10:7
3	accomplishments 17:13	12:1 15:5,17 19:1	appropriate 14:1 appropriateness
30 1:5	accountability	19:3 20:8 22:15	24:16
301-796-0674 1:13	12:19 14:2,22	24:17 25:17,18	approvals 13:14
31 1:10	12.19 14.2,22	27:16 29:4 32:5	approximately
35 33:7	accuracy 9:15	35:1 38:11 39:9	13:20
37 3:12	14:17,20 15:20	40:19	april 26:19
38 24:5,7,13	16:3 35:10	agency's 26:2	area 4:16,18 21:19
	accurate 47:6	ago 5:16 7:7,14,22	28:21
	achieve 15:1 26:20	33:1	asking 31:5

[aspects - clarity]

November 30, 2017

aspects 8:15 9:9	baseline 9:4 10:9	briefs 29:13	cause 12:4 16:7
assembled 18:9	20:17 29:5,10	bringing 4:17	causes 15:19
assess 14:19 16:14	40:2	broad 6:12	40:10
assessment 1:3 3:5	basic 10:20	broader 30:8	causing 13:13
7:10 9:4,7 10:9	basically 18:9	brut 6:4	cber 5:8 28:18
19:20 29:5,12	basis 23:5 24:20	bsufa 3:7 4:12 5:4	30:9,14,19 33:20
31:21 32:1 33:18	37:20	5:19 9:3 16:13	cder 5:8 7:7 18:1
39:20,22 40:12	began 20:14 22:16	18:14,20 20:4,6	28:17 30:9,14,14
46:9	23:11	21:8 25:9 26:14	33:20 34:9 45:20
assist 10:9	beginning 23:21	28:15,18,21 29:15	center 13:21 14:9
associate 2:5 18:5	behalf 37:14 44:21	32:20 38:6 39:3,6	20:9 22:17,17,20
26:22	behaviors 15:5	39:8,15 40:3,6,13	23:18 25:14 33:20
associated 8:11	believe 28:9 41:3	build 34:1 43:7	34:6,7
38:22	benchmarks 11:4	burden 23:8 34:20	centers 8:6 11:3
associations 27:17	32:7	bureaucracies	20:22 21:1 25:13
28:4	berman 2:4 3:6	4:22	26:4
assumptions	7:4,11	business 24:7	century 43:1 44:4
31:14	best 10:16 44:9	businesses 7:6	certificate 47:1
assure 24:16	45:14,18 47:6	с	48:1
atmospheric 32:9	48:3	c 2:1 3:1 4:1	certificates 23:6
attention 5:5 8:14	better 6:3 12:2		23:20
9:8 36:16	18:18 36:3	call 26:15	certify 47:3 48:2
attorney 47:11	beyond 40:3	called 5:5 38:10 42:11	challenge 40:16
attrition 19:12	biological 37:18		41:14
audio 48:3	38:6,8	calling 34:13	challenges 19:6
authorities 18:8	biologists 24:1	campus 1:10 28:1 cancelled 43:18	31:4
43:9 45:8,15	biosimilar 38:6,7	candidate 13:19	change 10:10
authority 7:22	38:20		45:16
automate 22:14	biosimilars 37:15	33:9,11	changed 31:10
automated 14:7	37:15,17,22 38:2	candidates 9:18 10:3 11:14 15:12	changes 38:18
avail 44:6	38:4,14,19 39:2,6		changing 45:11
availability 37:18	40:9,16,20	16:1 32:1 33:4 36:3	chantal 34:9
available 20:22	bit 13:4 20:2 21:7	capabilities 25:13	charged 39:12
22:10,19 23:21	bldg 1:10	29:3	chart 35:15
25:13 42:14	blue 20:3		check 4:13 29:7
avenue 1:11	board 24:15 34:7	capability 40:8	cheerful 18:11
averaging 19:13	bottlenecks 13:15	capacity 8:21 25:2	chemists 23:15
award 25:2	boundaries 32:4	25:18 29:3 40:8	cherry 44:9
awarded 25:4	box 4:13	capital 19:7 21:12	cheryl 48:2,13
awarding 24:19	brand 27:3	25:15	chief 2:8 33:21
b	break 36:17 37:4	care 34:19 46:7 career 22:9	43:11,16
	37:8	careers 28:10	choice 27:11
based 14:9 20:5	briefly 7:15		clarity 14:2
21:3		carry 39:7	

[class - date]

	20.1.20		1 47 0 11
class 6:20	39:1,20	confusion 12:18	counsel 47:8,11
classification	commitments	13:13,17	48:6
21:16,18 22:12,14	5:20 8:11 18:19	congress 20:11	couple 25:7 45:5
classified 22:1	20:4 21:17 23:2	consensus 37:20	coupled 45:14
clean 16:21	29:16 30:15,20	consequence	create 13:14 33:2
clear 39:9	40:14	14:13	33:8
climate 15:7	committed 8:20	consideration	creativity 15:8
clinical 2:6 18:6	25:8	38:15	credentialing
close 19:2 25:7	committee 5:9	considered 36:12	24:15
closely 34:2 35:16	33:19	consistent 20:10	critical 9:17 11:1
closing 3:13 25:21	commonly 23:3	40:4	16:1 21:14 23:4
43:13	38:10	constitutes 40:12	27:14 30:16 38:13
coincides 28:8	communication	contact 36:8	40:1 42:3
collaborating 34:2	9:20 13:3	content 16:4	crs 6:1
collaboration	communications	context 7:15,20	crucial 18:8
40:21	34:5 38:20	12:6	cultural 15:15
collaborative 13:2	companies 38:3	continue 6:19	culture 16:10
colleague 26:9	compared 11:4	16:12 19:5 40:17	cures 42:16 43:1
colleagues 41:19	compensation	44:1 45:18	43:10 44:4 45:15
collected 10:18	24:15 42:17	continued 25:22	current 5:15
11:10 12:3 14:15	competition 41:18	26:4,5 40:21	10:21 13:9 14:5
33:5	competitive 37:22	continues 21:19	21:15 30:2 31:7
collecting 36:10	41:15,17 44:8	40:16	42:8
collection 10:12	complete 29:7	continuing 40:19	currently 20:21
10:13 17:4 31:19	32:3 39:10	continuous 26:16	22:15,20 23:18
come 27:7 33:4	completed 24:8,20	29:12 39:13	42:14
43:19	complexity 12:15	contract 24:19	customer 9:16
comes 41:20	complicated 13:10	25:3,4 34:1	12:15 14:20 15:11
coming 44:22	comprehensive	contracted 43:6	15:21 16:5 31:22
comment 3:12	5:14 29:2	contractor 9:4	33:11 34:6,6,12
6:12 37:12 41:3	comprised 33:20	10:8,11 11:10	34:13 36:6,10
comments 6:16	34:7	12:4 16:8,14,19	customers 26:1
41:2 44:20 45:1	concerns 40:5	22:4 32:2,6	33:3,3
46:4	concluded 46:10	contractors 25:5	d
commissioner 2:3	concludes 29:14	control 9:11	d 4:1
2:5 4:6 7:8 18:5	36:14	controlled 16:21	data 10:12,13,16
33:22 43:4	conduct 9:4 10:8	conventional 31:4	10:17,19 11:10
commitment 4:12	11:19 17:9 26:16	copy 22:4	12:3,5 14:11,16
5:14 9:2,3 12:4	29:2 32:7	core 14:14,22 15:1	16:20 17:4 20:16
16:14 17:20 20:7	conducted 5:13	21:5,9	21:12,13 25:15
21:9 24:3,18 26:2	10:11 32:1	corporate 23:1,7	31:18,20 33:5
26:14 28:14 29:1	conference 27:21	23:12 24:2 28:6	databases 20:20
29:7,9,11 32:20	conferences 27:7	41:10,12	date 5:19 8:12
35:1 38:10,17			24:4,12 28:17

[date - establishing]

November 30, 2017

48:13	despite 6:1,1	dissatisfied 10:1	efforts 15:2 17:20
dates 29:11	detail 7:16 12:9	dive 13:6	25:8,10 26:10
dawson 34:9	13:5 17:14	docket 29:8 45:1	40:19
day 24:8 44:13	detailed 5:17	46:5	ehcm 21:5,7
days 10:22	detailee 34:8	dockets 6:14	either 6:22 22:1
decades 45:19	details 12:7 17:8	documentation	24:21 42:1
december 32:17	determined 12:11	12:12	emphasize 45:5
32:21 34:10 47:15	13:16	documented 35:22	employed 47:8,11
decision 17:8	develop 25:12	doing 19:18 43:21	48:7
21:13 25:15	37:21	donning 27:19	employee 9:15
decisions 25:20	developed 20:19	downstream	14:21 15:14,20
dedicated 39:11	developing 22:12	14:12	16:5 35:18 47:10
deep 13:6	27:3 32:15	dr 4:3 5:2,8 7:12	employees 35:19
deeper 31:8,13	development 38:4	8:9 18:15 33:22	employer 27:11
defined 13:8	39:17	36:19,21 41:2,3,4	enable 29:3 35:11
definitely 36:4	deviated 13:22	43:11,15 44:5,12	enables 43:4
degree 13:17	dhhs 34:3	44:15,17,17	enacted 43:1
delays 13:13	diagnosis 13:6	dragged 44:19	endpoints 30:7
deliberate 40:18	diagnostic 7:13	drive 15:19	engage 9:3
delight 33:15,16	15:4 33:5	driven 25:16	engaged 10:8
delve 7:19	dialogue 13:2	dropped 30:3	16:14 19:22 32:2
democratic 37:3	different 22:8	drug 1:2,9 8:16	32:6
dentist 41:11	23:13 28:11	41:18	engagement 13:22
dentists 24:6	difficult 14:22	drugs 13:21 30:17	26:5 34:13
department 8:1	15:3	dubbed 45:3	engine 30:11 36:9
deploy 27:4	dimension 41:14	due 14:17 15:13	enhancement 39:1
depth 33:7	dimensions 35:6	duration 40:3	ensure 25:1 39:15
deputy 2:3,8 4:6	direction 15:13	e	enthusiasm 45:21
18:2 33:21 43:11	47:5	e 2:1,1 3:1 4:1,1	entire 8:5 10:7
43:16	directly 34:14	e 2.1,1 5.1 4.1,1 earlier 28:10	entirely 30:3,11
describe 5:10	40:8	early 23:21 30:5	environment
description 21:21	director 2:7 17:15	30:22 32:15,19	21:15
descriptions 22:5	18:2,2 26:22	eclass 22:13,16,18	epidemiology
22:7	33:20	effective 15:6	30:18
design 16:20,21	discipline 15:8	effectively 36:1	equity 24:16
17:5 26:6 29:22	disciplines 41:11	effects 14:12	errors 9:19
31:4 32:7,10,13	discovered 31:21		escalation 35:13
designated 36:8	discuss 10:6 17:7	efficiency 12:21 37:2	establish 20:17
designed 13:7	17:12 26:14	efficient 13:9 15:6	21:17 27:15
17:6 23:3 31:15	discussing 5:18	38:12	established 22:7
33:13	6:7	effort 20:7 21:2	26:19
designing 31:6	discussion 4:15		establishing 21:20
32:14	discussions 40:5	23:2,11 24:4,20 39:7 42:18	26:15 28:3
		37.1 42:10	

[establishment - future]

November 30, 2017

establishment	extraordinarily	figures 10:21	force 6:4
39:10	15:3	fill 9:22 23:15,16	foregoing 47:3
evaluate 17:3	extremely 4:16	39:5 42:13	forgot 19:18
evaluate 17.5 evaluation 5:14	eye 17:7	filled 20:8,16	forthright 44:11
events 28:2	•	21:22 23:3	fortunately 43:18
events 28.2 eventually 30:10	f	final 6:7 24:18	43:19
eventually 30.10 evolved 20:18	facilitate 20:10	finally 11:5 13:1	forum 37:15,15,20
examine 9:10	fact 5:21	15:4	38:2 39:19 40:15
excellence 32:11	facts 10:20	financial 20:20	40:18
excellent 29:5	falling 18:6		forward 5:6 26:3
excited 41:5 42:21	far 27:16	financially 47:12 48:8	29:22 35:5 40:11
43:6 45:22	fda 1:3 3:5,7,10	- · -	
exciting 41:6	4:19 5:22 7:7,10	finding 13:1 findings 3:5 7:10	40:17,21 43:22 45:1 46:3
0	7:18,22 8:2,2,18	0	found 34:5
executing 15:9 execution 12:13	9:5,11 14:15	7:16,17 9:6 12:6,8 14:3 15:16 16:17	
	16:15 17:5,22		founding 38:2 four 7:7
executive 34:7 exercise 4:13	18:14,19 19:7,19	32:21 40:4	
exercise 4:13 exist 17:17	20:18 23:4 24:20	finish 30:5	fourth 12:20
	25:11,11,16,20	first 4:8,17 7:4,7	framework 12:5
existed 19:3	26:4,7 27:3,8,9,22	12:11 17:15 18:1	freeze 19:10
existing 20:20	28:12 29:17,19	20:1,5 34:8 39:3	freezes 6:2,2
exit 25:17	31:12 36:14 38:16	40:12 44:21 45:2	frequently 42:10
expanded 25:17	38:17,21 39:4,16	fiscal 19:9 38:9	friday 32:17
expanding 24:22	39:22 40:5,9,17	fitted 36:3	friendly 12:20
37:18	40:22 44:6,11	five 7:21 19:13	14:7
expansion 17:7	fda's 16:10 17:8	23:12,20 28:16	frustrated 9:18
expect 19:5 21:5	17:15 19:4,12	35:6	11:14,20 16:1,2
30:5 32:16	22:13 24:14 39:1	flexibilities 32:5	ftes 39:2
expected 14:1	39:19	41:16 43:4	fulfilling 16:13
21:5	fdara 8:19 18:7	flexibility 42:10	fulfillment 39:19
expended 39:8	45:15	flipping 45:12	full 17:20
experience 11:17	fearless 43:15	focus 5:12 9:9	fully 13:8
19:14	feature 38:22	25:22 28:21 34:13	functionality
expert 32:2	fee 8:11,14 24:22	35:4 36:5	21:10
expertise 38:12	38:6,15 45:9	focused 8:12 9:7	functioning 8:15
experts 32:10 43:7	feedback 4:15	15:9 21:22 25:16	functions 14:15
explain 7:21	36:11	29:9 30:9	fundamental 16:8
explore 13:4	feel 5:21 35:14,20	focusing 27:2	funded 20:8 39:7
explores 16:22	fees 39:8	30:19	further 15:1 22:11
extensive 10:11	felt 19:16	folks 19:19 28:12	22:14 34:12 39:9
32:10	feverishly 42:21	follow 32:4	47:10 future 6:6 10:14
external 10:11	fields 41:15	following 10:13	future 6:6 10:14
15:11 32:7,10	fighting 44:12	16:7,19	17:7 25:17 29:10
44:2	figure 19:17	food 1:2,9 8:15	29:11 30:10 31:16
			35:13 46:4

[g - incomplete]

November 30, 2017

g	growth 5:1 19:4	13:17,19,20 14:5	ii 3:7 4:13 9:3
g 4:1	h	14:11,14 15:6,9	16:13 18:14,21
gained 31:21	hampshire 1:11	15:12,18 16:2,15	20:4,6 25:9 26:14
gaps 19:2 40:1,7	handoffs 13:12	16:16 17:13,17	28:15,21 29:15
gather 20:16	hard 8:20 22:4	18:8,10,14,18,22	32:20 38:7 39:3,6
gathered 44:2	23:16	19:2,6,7,10,21	40:3,6,13
general 5:20		20:1,13 22:2 23:5	impact 40:8
getting 13:19 31:8	hashtag 18:10	23:9,20 24:5,9,11	impaired 16:12
give 42:9	45:3	24:21 25:11,19	imperative 44:1
0	health 8:1 9:11	26:7 27:8 28:14	impetus 7:21
given 30:6	26:3 32:8	28:14 29:2,17,19	implement 17:8
gives 45:10	healthcare 37:19	30:1 31:22 33:4,8	38:18
glad 43:17	hear 19:22	33:9,11,12 34:1	implementation
go 7:16 19:17 27:6	heard 21:13 36:2	34:14,19 35:9,19	8:10 29:22 30:8
27:18 28:1 31:5	hebert 2:8 43:14	36:7,11 39:9,22	32:16 40:20 43:3
35:14 37:5	43:15	40:7,13 42:22	implementing 8:3
goal 6:19 32:19	help 19:19 25:15	43:3 45:2,3,13,15	32:20 33:17 42:22
33:15	27:22 28:12 42:16	45:16,22	implication 7:17
goals 8:22 23:6	43:21	history 8:10	implications 10:18
38:8 39:10	helping 42:13	hold 39:21	important 4:19
going 5:12 7:8,14	herbert 3:14	home 14:9	15:15 24:14 27:21
9:8 12:6 26:9	hereto 47:11	hope 6:12	34:22 35:3 36:7
32:18 36:10,12	hhs 31:12	hoping 19:20	44:5
37:7,11 41:12	hi 43:14	house 20:19	improve 8:21
45:13	high 9:13,18 10:20	hr 19:8 20:20 21:5	20:13 21:20 22:11
good 4:3,5 7:11	11:1 12:8	21:9 25:5 34:18	25:10 38:19
14:11 18:15 37:13	higher 11:5 45:6	36:9	improved 20:1
43:14 44:7 46:6	highlighted 20:3	human 2:7 7:22	improvement 15:2
gottleib 44:12,17	highly 10:15	8:1,4,6 9:11 11:18	16:6 40:2
governance 33:17	hill 44:12,18	11:22 15:16 17:16	improvements
34:21	hire 6:4 9:17	18:18 19:7 21:12	8:11,12,16 10:4
government 31:12 42:8 45:19	10:22,22 15:22	25:15 34:3,4	17:5 19:21
grade 22:9	16:11 19:8 23:8	hypothesis 30:22	improving 8:20
granted 43:10	39:1 bired 7:1 2 24:12	i	25:22 26:2 37:19
gray 1:22 47:2,17	hired 7:1,2 24:12 28:17 34:8	idea 4:14	include 21:10
great 1:10 6:21	hires 11:8 16:15	ideas 34:15	included 31:18
41:11 45:17	28:15,16,21 33:8	identified 11:12	33:6
grew 20:7	hiring 1:3 3:5,7,10	14:19 23:10	includes 22:6
ground 31:2	4:8,11 5:14,20 6:1	identifies 40:1	30:13
groups 18:11	6:8,15,22 7:1,10	identify 27:22	including 19:9
34:13	7:17 8:3,5,5,17,20	37:9	20:1,11 22:18
growing 25:17	9:5,7,9,13,20,22	identifying 27:14	23:13 25:13 30:15
grown 4:21 14:9	10:4,7 11:7,15,16	40:10	incomplete 12:12
B	11:19 12:1,2 13:7		
	11.1912.1,213.7		

[incorporates - managers]

November 30, 2017

Page 7

incorporates	interface 36:9	kinds 27:1 28:11	leveraged 31:20
31:17	internal 44:3	43:8	leveraged 51.20
increase 38:21	interviews 33:7	know 6:14 27:19	20:20
incremental 10:3	34:18	31:19 32:3,12	leveraging 21:22
individual 23:9	introduce 7:3	34:18 37:6	42:14
individual's 28:10	introducing 22:16 introduction 3:3	knowledge 47:7 known 9:14	library 21:18 22:6 limitations 19:10
industries 20:12			-
industry 18:20	4:2 18:16	<u>l</u>	limited 15:16
23:2 27:17 38:18	inventory 31:11	lack 9:20 11:14,20	42:10
40:6 41:19	investigate 31:14	11:21 13:1 14:11	line 43:9
inefficiencies 40:1	involved 5:3 13:12	lacking 11:21 35:4	list 37:7
40:7	35:19	lacks 15:7	listening 11:11
infectious 45:21	involvement 15:14	ladders 22:9	little 13:4 20:2
inform 10:14	irene 1:22 47:2,17	large 25:3 39:5	21:7
information 20:10	issuance 24:9	larger 6:11 12:5	loan 34:10
21:7 26:10	issue 35:13	laselle 48:2,13	long 8:9 9:18
informed 10:16	issues 9:13,14	latest 8:13,18	look 8:20 26:3
initial 29:5 31:21	14:4 16:3	launch 16:20 21:6	30:10 33:10 40:21
32:21 39:20,22	iv 30:15	24:4 30:5 32:18	42:4 45:1 46:3
40:12	j	launched 22:15	looked 33:14 41:9
initiate 23:8	january 29:8	23:12 25:16	looking 9:22 35:5
initiative 20:14	34:11 43:1	launching 6:9	42:6
42:16	jennifer 37:9,14	lead 27:1 34:8	looks 33:13
initiatives 18:17	job 24:9	leader 43:15	loss 19:14
24:21 25:1	jobs 36:1	leaders 25:17	lot 6:13 11:11 27:7
innovation 18:9	join 18:12	leadership 15:10	28:19 32:12 34:21
innovations 39:17	joined 7:6 18:1,3	35:1	36:12 41:18 46:2
41:22	joining 25:22	leading 12:15,18	low 11:5 12:21
insight 31:17	jointly 43:21	12:21 13:2 42:17	14:1,2 19:12
instance 33:3	journey 32:14	learn 6:13	m
institutes 32:8	k	leave 25:20	main 12:8
institutions 28:4		led 12:12	major 14:12 40:10
insufficient 15:13	keep 6:20 19:4	lending 5:9	majority 13:21
insure 13:15 25:21	39:16 Izellon 2:5 3:0 11	length 9:19	38:3
37:21	keller 2:5 3:9,11	lengthy 10:21	making 17:19,19
insuring 33:2	18:3 26:9,13	letter 38:10,17	21:13 25:15,20
38:11	29:18 36:20 42:20	letters 9:3	32:12
integrated 12:21	kept 4:22	level 9:13 10:20	management 8:7
14:7 21:4	key 23:6 25:9	12:8 23:4 38:21	9:12 20:6 21:3,4
intended 20:1	33:18 38:14,22	42:17	21:11 35:11
intent 37:17	42:16	levels 13:22 19:1	manager 13:17
intention 45:11	kicked 32:15	20:9 22:9	33:9,11
interested 47:12	kind 18:16 34:9	leverage 21:3	managers 5:10 8:5
48:8		42:10	9:22 11:7,16 12:2
<u>L</u>	1	rtingCompany com	

www.CapitalReportingCompany.com 202-857-3376

[managers - ones]

November 30, 2017

	00 1 0 4 5 0 5 10		1 05 0 10 14
15:12 16:2,16	33:1 34:5 35:12	n	nowak 37:9,13,14
19:7 23:5 25:19	35:18	n 2:1 3:1,1 4:1	nudges 45:8
31:22 33:4,8	message 27:10	name 4:5 37:13	number 9:19
34:14,16 36:3,7	met 34:12	43:15	22:20 23:16 39:5
36:11 45:13	methods 6:10	names 16:4	numerous 11:12
manages 24:7	metrics 14:14,15	national 26:21	13:13
mangers 13:21	14:19,22 15:1	32:8,9	0
manner 28:5	17:4 35:3,6	nature 14:17	o 3:1 4:1
manpower 38:11	microbiologists	nearly 16:16	o'clock 36:18
manual 14:17	24:1	necessarily 13:15	oak 1:10
manually 20:15	mind 33:14 35:9	necessary 31:9	objectives 29:21
map 12:5	42:1	need 5:6 12:2 20:7	30:21,22
march 26:21	mindsets 15:5	23:9 27:9 35:4,19	observed 15:5,7
market 38:1 42:4	minimum 42:11	35:20 36:3 44:10	15:17
marketplace	minute 33:1 36:17	needed 25:2 38:12	occupation 43:8
38:14	mission 9:17 11:1	needing 16:6	occupations 9:17
maryland 47:19	15:22 23:3 26:3	needs 6:5,21 7:2	11:1 16:1 22:8
materials 22:19	30:16 37:16 44:11	10:15 21:21 22:2	23:13 24:11 28:10
math 23:13	modern 6:4 26:6	33:11	30:16
md 1:12 41:10	modernization	negotiations 5:4	oceanic 32:9
mean 41:8	10:10	8:14 18:21 25:9	october 22:16
meaningful 17:2 means 7:5	modernize 4:11 21:9	38:5,15 39:4 40:6	offer 21:12 24:10
		negotiators 38:18	41:17 44:8
measure 14:16	modified 22:2	neither 13:7 47:7	offering 22:17
36:13 40:2 media 27:4	module 21:4,11 moment 5:11	48:6	41:20 42:15
medical 8:6 11:2	momentum 40:17	network 32:10	office 2:7 7:8 8:3,6
19:15 24:6 26:5	monitored 35:16	never 35:13,16	9:12 11:22 15:16
39:11	months 15:22	46:1	17:16 18:18 20:9
medicines 37:19		new 1:11 6:9 10:7	22:2 26:5 30:17
meet 6:5 7:2 8:22	morning 4:3,5 7:11 18:15 37:13	16:15,22 18:4	30:17,18 34:3,3
18:19 22:2	43:14,18 44:22	20:21 21:3,5,10	39:11 41:5 42:3,4
meeting 4:8,9,12	45.14,18 44.22	21:21 22:15,17	officer 33:21
4:14 29:14 32:19	motivates 33:12	23:20 24:10,12,21	43:12,17 47:2
37:11 39:21 40:13	motivates 55.12 motivation 15:8	30:4,11,17 33:8	officers 24:6 34:8
43:18 45:4 46:9	move 5:6 29:18	39:10,17 43:7	offices 8:7 26:4
meetings 27:19	36:17 43:22	nice 41:20	30:16,20
melanie 2:5 3:9,11	moving 35:5	non 37:15 41:10	oh 37:7
18:3 26:9 42:7,17	mullin 5:3 41:3,4	41:10,19	ohr 17:15,18,18
43:20 44:4 45:3	mullin's 44:5	notary 47:1,18	18:1 19:18
melanie's 45:19	multi 25:3,3	note 15:15	ohr's 25:22
members 38:3	multiple 22:8	noted 11:21 16:6	okay 37:2,5
mentioned 7:12	31:17	23:22	once 12:3 30:7
8:9 18:22 21:11	51.17	november 1:5	ones 20:3
0.7 10.22 21.11		28:17	

[ongoing - press]

November 30, 2017

package 13:19	16:11,18 19:9	platform 45:10
24:8	27:7 36:21 37:3	please 6:18 37:10
packages 16:5	41:17,21 44:7,10	38:5 46:3,4
41:20 44:8	people's 16:4	pleased 18:16
page 3:2	percent 19:14	34:22
paid 8:15 9:8	30:13	pleasure 4:7 26:8
pain 11:12 33:14	performance 15:2	pledged 39:5
painful 20:16	17:3 35:10 38:8	plus 45:19
paradigm 45:16	period 10:12	podium 26:8
parallel 35:7	28:16	point 35:17 36:8
part 8:2,7,18 25:8	persona 33:9	pointed 17:16
27:20 33:5 38:5	personal 15:10	35:3 43:16 45:14
42:3	personnel 9:12	points 11:12 33:14
participating	perspectives	33:15,16 45:5
19:20	31:22	policies 9:12 31:12
particularly 5:2	pharmacologists	31:12,12
30:9	23:14	policy 32:1,3
parties 47:9,11	pharmacy 28:11	37:21
48:7	phase 21:2 22:11	poor 12:15,15,19
partners 18:20	42:2	12:22 13:2 14:8
20:15 22:20 23:2	physician 24:10	14:14 15:9,19
23:19 44:2,3	24:14	populating 34:11
partnership 19:19	physicians 24:12	portfolio 25:12
partnerships 26:4	38:2	portfolios 38:4
party 9:3	picking 44:9	portion 29:14
passed 8:19	piece 6:7	position 18:4 20:5
path 29:22 40:11	pilot 3:10 6:8	20:19 21:2,3,11
patients 38:1	16:21 17:3,6,9,14	21:16,21,21 22:5
pay 24:16 43:3,5,7	18:7 19:21 21:1	22:6,13
paying 45:19	28:20 29:17,19	positions 20:8,17
pd 21:18 22:5	30:1,4,5,13 31:1	23:4,16 24:1
-	32:13,15,19 33:19	27:14 28:7 30:3
-	34:1,9,11,21 35:2	30:12 37:21 39:5
5:19 9:2 16:13		42:13,16
18:14,20 20:3,6		possible 5:7
	-	practices 5:15
	_ ▲	10:16
	place 6:21 17:18	predictable 23:6
30:15,19 32:20		prepared 48:3
39:15	plan 20:13 25:16	preparing 13:18
peer 32:7	26:20	present 7:9,12 9:5
pending 6:2	planning 20:9	presented 41:9
pending 6:2 people 6:14 11:11 13:11 14:4 16:10	planning 20:9 25:12 32:16	presented 41:9 press 20:12
	24:8 packages 16:5 41:20 44:8 page 3:2 paid 8:15 9:8 pain 11:12 33:14 painful 20:16 paradigm 45:16 parallel 35:7 part 8:2,7,18 25:8 27:20 33:5 38:5 42:3 participating 19:20 particularly 5:2 30:9 parties 47:9,11 48:7 partners 18:20 20:15 22:20 23:2 23:19 44:2,3 partnership 19:19 partnerships 26:4 party 9:3 passed 8:19 path 29:22 40:11 patients 38:1 pay 24:16 43:3,5,7 paying 45:19 pd 21:18 22:5 pds 22:1 pdufa 3:7 4:12 5:4 5:19 9:2 16:13 18:14,20 20:3,6 21:8,17 24:3,18 25:9 26:13 28:15 28:18,20 29:15 30:15,19 32:20 39:15	24:8 27:7 36:21 37:3 packages 16:5 41:20 44:8 page 3:2 people's 16:4 paid 8:15 9:8 30:13 pain 11:12 33:14 percent 19:14 pain 11:12 33:14 performance 15:2 paradigm 45:16 paradigm 45:16 parallel 35:7 part part 8:2,7,18 25:8 persona 33:9 27:20 33:5 38:5 personal 15:10 42:3 personal 15:10 participating perspectives 19:20 31:22 partners 18:20 23:14 partners 18:20 24:14 partners 18:20 24:14 partnership 19:19 phsicians 24:10 partnership 26:4 party 9:3 passed 8:19 picking 44:9 paients 38:1 picking 44:9 paients 38:1 paients 38:1 paying 45:19 30:1,4,5,13 31:1 pdufa 3:7 4:12 5:4 35:11 36:13,15 25:9 26:13 28:15 28:19 30:1,4,5,13 31:1 30:15,19 32:20 pilot's 29:20 pilot's 29:20 pilot's 29:20 pilot's 29:20 pilace 6:21 17:18

[pressure - reimagine]

November 30, 2017

Page 10

		1	
pressure 32:6	profiles 25:14	questionable	recommended
primarily 27:2	profit 37:16	14:17	16:19 17:3,6
30:19	program 8:3 24:9	questions 31:13	reconfigured
primary 5:13	28:11 38:6,19	44:20	16:22
principal 2:3 4:6	39:1,3,7 40:10,16	quick 25:1 36:19	record 47:6
33:21	40:20	quickly 5:6 32:12	recorded 47:4
principles 4:17	programs 4:10	quite 29:7 42:2	recruit 23:9 27:22
priority 45:6	19:16 24:22 25:19	r	28:5 45:18
proactive 27:13	30:17	r 2:1 4:1	recruited 18:4
procedures 35:22	progress 3:7 5:19	rachel 2:3 3:4 4:5	26:20
38:9	17:19 18:14 29:16	43:16 44:15	recruiting 18:7
proceeding 47:3	31:1 32:13	range 25:5 30:15	26:16 27:10 28:1
proceedings 47:4	project 19:22	rapid 35:12,12	39:13 41:10,13
47:6	20:18 21:9 43:22	39:17	42:2
process 4:11,11	proliferation 14:9	rapidly 4:21	recruitment 2:6
8:17,21 9:14,19	provide 17:13	rate 11:2 19:12	18:6 23:1,7,12
9:21 10:2 11:15	23:5 25:4 26:1,10	rates 11:3 14:8	27:3,15,19 28:6
11:17,18,19 12:1	29:20	reach 27:16 28:7	28:19
12:11,13,14,18	provided 29:4	reached 30:7	recurring 23:4
13:7,10,11,14,20	45:9	read 6:17	redesign 16:9
14:2,3,5,11,16,20	provides 29:10	ready 25:1,5	reduce 23:7,8
14:22 15:6,9,18	providing 25:14	real 31:1 35:12	34:20
16:2,3,9,10,15,17	27:20 38:1 40:11	realize 28:12	reduced 24:11
18:19 22:14,18	provisions 42:22	really 5:22 6:15	47:5
23:15 24:8,10,13	public 3:12 4:8,20	27:3,9,13,21 29:9	reducing 35:8
26:7 29:2 30:4,11	20:12 26:3 37:12	29:9 31:6,8,9,13	referring 43:8
31:2,6,14 32:11	39:21 47:1,18	32:2 33:10 35:2,4	refers 18:10
33:2,12,13 34:15	publish 39:20	35:4,8 36:10,15	refine 6:10 17:4
34:19 35:9,10,15	published 5:16	42:16,21 43:6	reflected 38:7,17
35:19 38:13,22	7:13 29:6	45:6,15	regained 7:22
39:4 40:6 41:22	pulled 30:3	realm 6:13	regard 12:1
43:22	punt 42:18	reasons 25:19	regarding 13:17
processes 4:22	purpose 4:9	31:8	14:3 16:17
6:10 40:8	put 45:4	reauthorization	regards 15:18
product 8:6 11:2	q	8:18 38:8	registered 36:22
38:6,8,13,20	qualitative 33:6	recap 16:13	37:1
products 26:6	quality 9:16 10:2	receipt 24:8	regular 24:20
39:11,15	11:6 13:15 14:20	recognition 11:20	regulated 20:11
professional 26:18	15:21 21:13 36:2	15:11	regulation 32:4
27:17 28:4			regulations 42:9
professionals	quantitative 11:9 11:10 33:6	recognize 19:1 recognized 35:20	regulatory 8:13
19:16		recognized 55:20	8:22 19:15
professions 23:16	quest 37:2 question 31:6	3:5 7:10 17:9	reimagine 3:10
_			29:17 31:16
	36:19 41:7 44:5	33:18 40:11	

www.CapitalReportingCompany.com 202-857-3376

[reimagined - speaker]

November 30, 2017

reimagined 29:19	42:2,15	scientific 2:6 4:16	sherman 2:3 3:4
30:11 36:15	return 36:18	6:13 18:5,7 26:15	4:3,6 7:12 8:9
related 47:8 48:6	review 7:20 12:6	26:17,22 27:6	17:11 18:16 33:22
relationship 40:22	16:19 29:2 32:3	28:1 39:14 42:4	36:19,21 37:6
relationships 28:3	38:13,19,22 39:2	42:13	41:2 43:11,16
relative 47:10	39:6,14 40:16	scientists 19:15	44:15,17
relatively 9:14	reward 11:20	scope 29:20 30:6	shortly 6:8 17:9
remain 29:8	rewarded 35:20	search 26:21	28:22
remarkable 5:22	rewards 15:10	searchable 22:7	showed 13:6 15:4
rendered 15:2	right 16:11,11,11	seated 4:4	shows 28:15
report 5:16 7:9,13	26:21 27:2 36:4,4	secondly 12:14	significant 13:16
7:15,20,21 9:9	rigorous 17:4	security 21:14	13:21 14:4 15:10
12:9 29:6 32:21	robust 38:12	see 19:17 22:22	16:17 21:19 30:13
36:2 39:20 40:1	role 17:5	29:11 32:18 43:11	31:18 38:4 40:12
report's 40:4	roles 12:17 16:22	seeing 11:3	significantly 11:5
reported 1:22	36:4	seen 9:13	12:9
13:22	rolling 22:21	select 30:16	silo 17:17
reporting 11:7	room 1:10 31:18	selected 24:10	silver 1:12
represent 38:3	root 12:4 15:19	semi 11:9	simple 13:8
represented 41:19	16:7 40:10	send 46:4	single 36:8
required 39:16	rooted 30:21	sending 45:20	singled 8:17
research 2:4 7:5	roughly 7:21	senior 5:10 35:1	sit 31:18
resolve 35:15	round 8:14 23:19	sentence 46:1	sitting 5:8 34:16
resource 22:19	routed 33:1	september 32:16	six 14:6 15:22
resources 2:7 5:5	run 30:2,4,6	series 23:20	19:13 20:2 33:6
7:22 8:4,7 11:18	running 30:11	seriously 6:17	size 19:13
11:22 15:17 17:16	S	45:7	skilled 19:14
18:18 34:3,4 45:9	s 2:1 3:1 4:1	serve 4:20 6:11	skills 25:6 47:7
respectful 40:22	safe 37:22	service 9:16 15:21	skip 37:3
response 42:8	saleries 41:17	16:5 26:1 36:6,11	slackers 41:20
responsibilities	42:1,5	services 8:1 9:11	slide 41:9
12:18	satisfaction 9:15	set 39:9 43:5	slides 13:5
responsible 13:18	11:6 12:16 14:21	sets 40:2	slightly 22:2
responsive 10:15	14:21 15:21 16:6	seven 28:18	smaller 20:22
rest 22:22 42:18	35:18	share 18:17 21:7	social 27:4
resulted 14:8	satisfied 11:7,8,16	25:7,18 28:22	solutions 14:10
results 7:9 13:6	satisfy 45:13	29:21	soon 43:2
38:7	saying 11:12	shared 15:13	sorry 37:6
retain 44:7,10	scale 25:3 30:7	sharepoint 22:5	sort 34:19
45:18	scaled 31:3	34:4	sources 17:1 31:17
retention 1:3 3:7	scenes 42:22	sharing 20:10	speak 7:14 36:22
4:8,11 6:22 9:8	schedule 23:6	29:19	37:1
18:14 26:17 39:13	34:18	sheet 16:21	speaker 7:3,4 37:5
39:22 40:7,13			

[speakers - think]

November 30, 2017

Page 12

[1	1	1
speakers 17:12	stats 23:13	25:10,15 26:2	targeted 27:12
speaking 28:6	steering 5:9 33:19	34:2 38:12 39:2,6	28:11,15 43:10
37:14	stem 28:9	40:9	targeting 28:9,20
special 8:14 24:21	step 13:12 22:18	supporting 19:21	team 18:7,10 24:5
24:22	22:18 31:14 40:12	22:18 45:21	24:5,7,13 26:16
specialists 11:18	steps 13:10,13	supports 24:5,14	27:1 31:4 32:14
specific 20:3 21:8	steve 7:4,4 17:11	sure 5:4 6:20	33:1 34:1,4,5,9,11
specified 9:2	17:16 29:4 35:3	35:21 36:20 44:7	42:8 44:1 45:2,3
speed 40:18	steven 2:4 3:6	surge 25:2	team's 30:21
spelling 16:4	strategic 28:3	surprised 27:8	teams 19:7
spending 44:22	30:17	surveillance 30:18	technical 8:13,22
spent 11:11 22:12	strategically	survey 13:20	26:17 39:14
27:21	20:13	25:18	technologies 17:1
spite 19:6	strategies 23:12	surveyed 16:16,16	teeing 28:5
sponsoring 44:15	27:12	surveys 33:7	tell 20:15
sponsors 38:20	strategy 23:7 27:5	sustainable 37:22	ten 17:22 24:7
spring 1:12 24:2	27:15	system 6:4 8:5 9:5	36:18
staff 8:21 17:21	streamline 24:13	10:4,7 14:13 16:9	tentative 24:9
19:8,15 25:20	structure 43:7	20:19 21:5,10	terms 6:1
26:15,18,19,20	struggle 8:4,8	22:13,19	test 32:6
27:14,18 39:14	struggled 8:2	systematically	testifying 44:19
44:9	studies 7:5	10:8	testing 6:9 30:22
staffed 39:16	study 6:17	systems 7:6 12:20	31:2 34:16 35:12
staffers 27:6	sub 13:11	14:5,6,8,18 16:18	thank 7:11 17:10
staffing 26:16,17	subsequent 29:12	20:21	17:11 18:13,15
27:1 29:3 39:13	substantial 8:10	t	26:12,13 36:15
40:15 42:4	12:12,14	t 3:1,1	37:10 41:1,2,4
stakeholder 16:22	success 33:12 35:5	table 27:8	43:20 44:14,14,16
stakeholders	36:13 38:13	table 27.8	44:17,22
11:13 20:11 38:16	successes 29:4	take 6:17,18 10:22	thanks 42:20
standard 35:22	successful 8:3,10	15:22 34:19 38:5	therapies 39:18
standardized 13:9	24:4 35:2	46:7	theresa 5:3 43:9
start 30:4 39:6	successfully 23:15	taken 47:3,9	44:5
43:2	succession 25:16	takes 9:17	thing 28:2 31:11
started 17:18	suffers 12:14	talent 17:1 39:16	36:2
starting 10:12	suggested 16:8	talk 10:18 20:2,5	things 5:13 9:10
32:17 41:16	sum 13:8	24:18 29:21	16:3 27:1 35:7
state 5:15 10:15	summary 5:17	talked 31:22	41:8
10:21 13:9 14:13	summer 10:13	talking 10:17	think 4:7 27:6
30:2,10 31:7,16	18:4 20:15 25:4	34:14	29:6 34:17 35:3
47:19	support 5:7 12:2,4	tania 2:7 3:8	37:11 41:9 42:21
states 37:17,21	14:5 15:6 17:2	17:15,21,22 26:13	43:2,8 45:14,18
statisticians 23:14	18:18 20:1,9	28:6 34:3 41:9	45:22
	21:12 24:5,21	42:20 43:20	

www.CapitalReportingCompany.com 202-857-3376

[thinking - yelled]

November 30, 2017

4 him lain a 20,11	4.1.1.1	29.15 45.0	
thinking 32:11	transparency 4:14	38:15 45:9	welcome 4:7
third 9:3 12:17	10:2 11:15 12:22	users 22:19	white 1:10
thought 46:1	38:21	utilization 14:8	who've 19:8
thoughts 6:16	tremendous 45:10	V	wide 12:1 17:5
three 5:12 28:17	trend 19:5	vacancies 10:1	22:15 25:5,18
thursday 1:5	tried 10:4	20:8 28:8 30:14	wisdom 5:9 31:4
time 9:10,16 10:22	true 47:6	vacancy 11:2,3	wonder 41:13
11:11 16:11 21:21	trust 15:7	vacant 20:17	woodcock 5:8
23:7,9 27:21 35:8	try 42:1	vacuum 31:3	words 46:1
35:12 44:22	tse 2:7 3:8 17:15	value 33:3	work 6:21 7:1,6
timeliness 9:15	18:15 42:7 43:20	variation 12:13	10:14 23:22 24:14
11:15 12:15 14:16	turn 26:8	variety 22:8	26:6 28:13 31:2
15:20 35:7	tutorial 19:18	various 11:13 22:8	43:21 44:1 45:10
times 17:17 24:11	two 5:16,20 7:14	34:12 41:10	45:17
36:4	17:12 22:3 45:19	varying 22:9	worked 4:15 19:8
tireless 17:20	46:1	varying 22:9 vehicle 31:1	20:14 22:3 25:2
title 24:5,7,13	typewriting 47:5	vendor 25:3	25:11
tobacco 26:6	typical 33:8	vendor 25:5 vi 3:7 4:12 9:2	workflow 17:2
39:12	u	16:13 18:14,20	workforce 4:20
today 5:12,17 7:4	u.s. 1:2,9 38:4	20:3,6 25:9 26:14	6:20 25:12
9:6 10:6 18:17	umbrella 18:6		working 23:18
19:22 20:2 24:19		28:15,18,20 29:15 30:19 32:20	25:10 27:5 28:2
25:22 26:14 29:6	unclear 12:17		40:22 42:21 45:3
37:14 44:3	15:13 uncover 31:9	vision 15:14 44:11 voiced 40:5	workplace 25:14
today's 4:9			works 24:15 37:20
tool 18:8 20:21	undergoing 41:12 understand 5:15	W	world 6:20
21:18 22:14,17	understands 7:6	wait 4:3	y
tools 21:10 42:9	40:15	want 6:3,3,4,4 7:2	year 10:12 19:9,10
42:14		19:6 25:7,21	-
top 11:9 35:9,14	underway 18:17	28:13 35:11,13	19:11 21:6 22:12
touched 6:22	26:22 28:19	43:20 44:14 45:17	22:22 25:3 28:16
tough 42:12	unit 39:11,12	wants 36:22	30:6 39:3
toxicologists	united 37:17,21	way 5:22 16:12	years 5:21,22 7:7
23:14	university 25:11	26:11 27:13 43:10	7:22 17:22 19:3,5
track 20:7,16	unprecedented	we've 4:21 5:13,19	22:3 38:9
tracking 14:14	19:1	17:18 20:4 22:12	yelled 37:11
17:2 20:19	update 4:9 29:15	23:11 24:12 26:19	
trade 20:12	updates 46:3	28:17 29:8 30:14	
training 11:21,21	urges 40:17	32:6,12 33:13	
22:17 27:20 35:21	use 8:16 22:10,20	34:8,12	
transcriber 48:1	46:1	weak 15:11	
transcript 48:3	useable 22:5	web 5:16 7:14	
transformational	useful 7:20	weeks 5:16 7:14	
10:10	user 8:11,14 12:20		
10110	14:7 24:22 38:6		